_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
504169870,7/17/2014 10:43:13,,1325148555,7/17/2014 10:42:56,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169870,7/17/2014 11:31:28,,1325185516,7/17/2014 11:30:56,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169870,7/17/2014 12:11:27,,1325215460,7/17/2014 12:11:10,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169870,7/17/2014 12:12:44,,1325216450,7/17/2014 12:12:30,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169870,7/17/2014 12:26:41,,1325227137,7/17/2014 12:26:12,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169870,7/17/2014 13:03:30,,1325257908,7/17/2014 13:03:08,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169870,7/17/2014 14:02:35,,1325313398,7/17/2014 14:02:17,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,FLUORIDE SUPPLEMENTS treats CARIES,73,49,,78,69,treats,0.979957887012223,907310-FS1-2,The scientific evidence supports the efficacy of FLUORIDE SUPPLEMENTS in CARIES prevention but there is weaker support for their effectiveness.,CARIES,FLUORIDE SUPPLEMENTS,RO-may_prevent
504169871,7/17/2014 10:26:43,,1325135256,7/17/2014 10:25:25,bitcoinget,1.0,28158287,USA,CA,San Jose,71.202.186.225,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169871,7/17/2014 10:33:56,,1325141292,7/17/2014 10:33:42,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169871,7/17/2014 10:43:40,,1325148934,7/17/2014 10:43:14,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169871,7/17/2014 11:23:22,,1325179395,7/17/2014 11:22:53,prodege,0.5754,27934334,GBR,"","",86.130.153.15,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169871,7/17/2014 12:56:57,,1325252089,7/17/2014 12:56:50,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169871,7/17/2014 13:04:54,,1325259290,7/17/2014 13:04:29,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169871,7/17/2014 14:01:09,,1325311860,7/17/2014 14:00:57,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,MYCOBACTERIUM LEPRAE causes LEPROSY,68,0,,87,7,causes,0.959403223600247,903748-FS1-4,"LEPROSY is unique in terms of the nature of the causative organism (MYCOBACTERIUM LEPRAE the chronicity of the disease, its prolonged treatment and the definitions of cure and relapse.",MYCOBACTERIUM LEPRAE,LEPROSY,RO-has_causative_agent
504169872,7/17/2014 10:26:43,,1325135255,7/17/2014 10:25:25,bitcoinget,1.0,28158287,USA,CA,San Jose,71.202.186.225,HEADACHE causes POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169872,7/17/2014 10:30:44,,1325138492,7/17/2014 10:30:38,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169872,7/17/2014 10:32:33,,1325140077,7/17/2014 10:32:05,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169872,7/17/2014 11:08:44,,1325167801,7/17/2014 11:08:28,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169872,7/17/2014 11:49:14,,1325199685,7/17/2014 11:48:28,instagc,0.6489,13763729,USA,"","",75.182.89.225,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169872,7/17/2014 12:29:52,,1325229819,7/17/2014 12:29:20,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169872,7/17/2014 12:54:16,,1325250010,7/17/2014 12:54:04,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS causes HEADACHE,66,122,,73,187,causes,0.99124070716193,902730-FS1-4,"The authors report a case of a 13 year old boy who presented with HEADACHE unsteadiness, diplopia and papilloedema due to POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS.",HEADACHE,POSTERIOR FOSSA MEDULLOBLASTOMA CAUSING OBSTRUCTIVE HYDROCEPHALUS,RO-disease_may_have_finding
504169873,7/17/2014 10:31:17,,1325138943,7/17/2014 10:30:48,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169873,7/17/2014 10:34:38,,1325141880,7/17/2014 10:34:26,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169873,7/17/2014 11:07:27,,1325166696,7/17/2014 11:07:09,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169873,7/17/2014 11:28:22,,1325182814,7/17/2014 11:28:08,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169873,7/17/2014 12:29:52,,1325229818,7/17/2014 12:29:20,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169873,7/17/2014 13:17:50,,1325269929,7/17/2014 13:17:11,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169873,7/17/2014 13:35:32,,1325288185,7/17/2014 13:35:14,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,MYOSITIS OSSIFICANS PROGRESSIVA causes PROGRESSIVE OSSIFICATION,78,0,,101,31,causes,0.997054485501582,901735-FS1-4,"MYOSITIS OSSIFICANS PROGRESSIVA is an autosomal dominant disease resulting in PROGRESSIVE OSSIFICATION and skeletal deformities, mainly in the connective tissue of muscle.",PROGRESSIVE OSSIFICATION,MYOSITIS OSSIFICANS PROGRESSIVA,RO-disease_has_finding
504169874,7/17/2014 10:21:17,,1325131140,7/17/2014 10:21:01,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,ABNORMALITIES OF BONE TURNOVER STRUCTURE causes PAGET'S DISEASE,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169874,7/17/2014 11:15:27,,1325173432,7/17/2014 11:15:09,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169874,7/17/2014 11:29:16,,1325183471,7/17/2014 11:28:41,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,PAGET'S DISEASE causes ABNORMALITIES OF BONE TURNOVER STRUCTURE,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169874,7/17/2014 11:32:17,,1325186309,7/17/2014 11:31:16,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,PAGET'S DISEASE causes ABNORMALITIES OF BONE TURNOVER STRUCTURE,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169874,7/17/2014 11:47:06,,1325198012,7/17/2014 11:46:43,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169874,7/17/2014 11:56:16,,1325204367,7/17/2014 11:55:52,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169874,7/17/2014 12:26:41,,1325227127,7/17/2014 12:26:12,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,PAGET'S DISEASE causes ABNORMALITIES OF BONE TURNOVER STRUCTURE,61,0,,100,15,causes,0.997054485501582,905143-FS1-4,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE,RO-has_finding_site
504169875,7/17/2014 10:21:53,,1325131600,7/17/2014 10:21:45,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169875,7/17/2014 10:43:38,,1325148918,7/17/2014 10:43:17,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,SKIN SPECIFIC PEMPHIGUS VULGARIS causes ANTIGENIC PROPERTIES OF SKIN,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169875,7/17/2014 10:43:40,,1325148935,7/17/2014 10:43:14,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,SKIN SPECIFIC PEMPHIGUS VULGARIS causes ANTIGENIC PROPERTIES OF SKIN,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169875,7/17/2014 11:07:27,,1325166701,7/17/2014 11:07:09,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,no_relation,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169875,7/17/2014 11:08:33,,1325167671,7/17/2014 11:07:31,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,ANTIGENIC PROPERTIES OF SKIN causes SKIN SPECIFIC PEMPHIGUS VULGARIS,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169875,7/17/2014 12:11:07,,1325215177,7/17/2014 12:10:36,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,ANTIGENIC PROPERTIES OF SKIN causes SKIN SPECIFIC PEMPHIGUS VULGARIS,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169875,7/17/2014 12:27:29,,1325227798,7/17/2014 12:26:59,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,109,188,,136,220,causes,0.516397779494322,902125-FS1-4,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169876,7/17/2014 10:33:56,,1325141310,7/17/2014 10:33:42,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,TUBERCULOSIS diagnosed by TUBERCULIN TESTING,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169876,7/17/2014 11:25:53,,1325181106,7/17/2014 11:25:11,prodege,0.5754,27934334,GBR,"","",86.130.153.15,TUBERCULOSIS diagnosed by TUBERCULIN TESTING,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169876,7/17/2014 11:31:15,,1325185280,7/17/2014 11:30:37,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,TUBERCULOSIS diagnosed by TUBERCULIN TESTING,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169876,7/17/2014 11:47:06,,1325198021,7/17/2014 11:46:43,instagc,0.6489,13763729,USA,"","",75.182.89.225,TUBERCULOSIS diagnosed by TUBERCULIN TESTING,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169876,7/17/2014 12:28:13,,1325228495,7/17/2014 12:27:30,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,TUBERCULOSIS diagnosed by TUBERCULIN TESTING,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169876,7/17/2014 12:54:30,,1325250150,7/17/2014 12:54:18,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,TUBERCULOSIS diagnosed by TUBERCULIN TESTING,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169876,7/17/2014 13:18:45,,1325270815,7/17/2014 13:17:51,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,216,160,,227,178,diagnosed by,0.987829161147262,906799-FS1-13,"In 1954, 70 of the 210 survey areas of the previous year were re surveyed in order to assess the trends in types and extent of tuberculosis and in reactions to TUBERCULIN TESTING during the year and to determine the TUBERCULOSIS incidence.",TUBERCULOSIS,TUBERCULIN TESTING,RO-may_diagnose
504169877,7/17/2014 10:31:59,,1325139683,7/17/2014 10:31:37,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,HEPATITIS B INFECTION treats HEPATITIS B VACCINE,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169877,7/17/2014 10:35:15,,1325142509,7/17/2014 10:35:05,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,HEPATITIS B VACCINE treats HEPATITIS B INFECTION,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169877,7/17/2014 12:57:35,,1325252588,7/17/2014 12:57:25,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,HEPATITIS B VACCINE treats HEPATITIS B INFECTION,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169877,7/17/2014 13:21:50,,1325273540,7/17/2014 13:21:00,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169877,7/17/2014 13:36:51,,1325289203,7/17/2014 13:36:29,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169877,7/17/2014 13:54:31,,1325305509,7/17/2014 13:53:59,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,HEPATITIS B VACCINE treats HEPATITIS B INFECTION,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169877,7/17/2014 14:02:03,,1325312869,7/17/2014 14:01:44,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,218,151,,238,170,treats,0.964763821237732,907208-FS1-2,"The protocols for the practical management of these cases, including the immunisation of susceptible non human primates and the staff with recombinant HEPATITIS B VACCINE are described, and the origin and evolution of HEPATITIS B INFECTION in primates are discussed.",HEPATITIS B INFECTION,HEPATITIS B VACCINE,RO-may_prevent
504169878,7/17/2014 11:06:45,,1325166210,7/17/2014 11:06:29,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,DIABETIC NEUROPATHY causes DIABETES,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169878,7/17/2014 11:30:21,,1325184558,7/17/2014 11:29:49,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,DIABETES causes DIABETIC NEUROPATHY,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169878,7/17/2014 12:55:44,,1325251225,7/17/2014 12:55:17,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,DIABETES causes DIABETIC NEUROPATHY,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169878,7/17/2014 13:34:52,,1325287605,7/17/2014 13:34:36,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169878,7/17/2014 13:56:58,,1325307734,7/17/2014 13:56:30,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,DIABETES causes DIABETIC NEUROPATHY,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169878,7/17/2014 14:00:41,,1325311396,7/17/2014 14:00:26,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,DIABETES causes DIABETIC NEUROPATHY,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169878,7/17/2014 14:03:32,,1325314190,7/17/2014 14:03:11,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,DIABETES causes DIABETIC NEUROPATHY,153,88,,171,96,causes,0.9,900234-FS1-4,A myo inositol related defect in nerve sodium potassium ATPase activity in experimental DIABETES has been suggested as a possible pathogenetic factor in DIABETIC NEUROPATHY,DIABETIC NEUROPATHY,DIABETES,RO-cause_of
504169879,7/17/2014 10:34:26,,1325141714,7/17/2014 10:34:15,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,BOWEL PERFORATION causes MECONIUM PERITONITIS,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169879,7/17/2014 10:44:09,,1325149267,7/17/2014 10:43:38,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,BOWEL PERFORATION causes MECONIUM PERITONITIS,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169879,7/17/2014 11:09:24,,1325168243,7/17/2014 11:09:13,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,MECONIUM PERITONITIS causes BOWEL PERFORATION,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169879,7/17/2014 11:28:22,,1325182822,7/17/2014 11:28:08,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,BOWEL PERFORATION causes MECONIUM PERITONITIS,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169879,7/17/2014 11:48:02,,1325198703,7/17/2014 11:47:39,instagc,0.6489,13763729,USA,"","",75.182.89.225,BOWEL PERFORATION causes MECONIUM PERITONITIS,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169879,7/17/2014 11:58:14,,1325205655,7/17/2014 11:57:40,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,MECONIUM PERITONITIS causes BOWEL PERFORATION,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169879,7/17/2014 12:10:19,,1325214484,7/17/2014 12:10:08,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,MECONIUM PERITONITIS causes BOWEL PERFORATION,0,70,,19,87,causes,0.972271824131503,900224-FS1-4,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION,RO-cause_of
504169880,7/17/2014 10:34:23,,1325141670,7/17/2014 10:33:57,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,BRAIN is location of CEREBRAL ISCHEMIA,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169880,7/17/2014 10:45:20,,1325150140,7/17/2014 10:45:01,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,BRAIN is location of CEREBRAL ISCHEMIA,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169880,7/17/2014 12:54:03,,1325249842,7/17/2014 12:53:53,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,BRAIN is location of CEREBRAL ISCHEMIA,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169880,7/17/2014 13:18:45,,1325270804,7/17/2014 13:17:51,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,BRAIN is location of CEREBRAL ISCHEMIA,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169880,7/17/2014 13:22:57,,1325274524,7/17/2014 13:22:29,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,BRAIN is location of CEREBRAL ISCHEMIA,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169880,7/17/2014 13:32:17,,1325285351,7/17/2014 13:31:55,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,BRAIN is location of CEREBRAL ISCHEMIA,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169880,7/17/2014 13:58:30,,1325309286,7/17/2014 13:58:04,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,71,110,,75,127,is location of,0.949157995752499,902113-FS1-9,The results indicate that the function of the inhibitory system in the BRAIN is selectively vulnerable during CEREBRAL ISCHEMIA,BRAIN,CEREBRAL ISCHEMIA,RO-disease_has_primary_anatomic_site
504169881,7/17/2014 10:45:00,,1325149954,7/17/2014 10:44:39,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,MEN2A causes PRIMARY HYPERPARATHYROIDISM,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169881,7/17/2014 11:14:14,,1325172423,7/17/2014 11:13:58,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169881,7/17/2014 11:50:31,,1325200512,7/17/2014 11:50:07,instagc,0.6489,13763729,USA,"","",75.182.89.225,PRIMARY HYPERPARATHYROIDISM causes MEN2A,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169881,7/17/2014 12:12:13,,1325216035,7/17/2014 12:11:49,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,MEN2A causes PRIMARY HYPERPARATHYROIDISM,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169881,7/17/2014 12:13:34,,1325216988,7/17/2014 12:12:43,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169881,7/17/2014 13:08:55,,1325262453,7/17/2014 13:08:39,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,MEN2A causes PRIMARY HYPERPARATHYROIDISM,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169881,7/17/2014 14:02:03,,1325312856,7/17/2014 14:01:44,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,MEN2A causes PRIMARY HYPERPARATHYROIDISM,62,139,,88,144,causes,0.717137165600636,906333-FS1-4,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169882,7/17/2014 11:45:47,,1325197099,7/17/2014 11:45:16,instagc,0.6489,13763729,USA,"","",75.182.89.225,PPD treats TB,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169882,7/17/2014 12:10:33,,1325214640,7/17/2014 12:10:14,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,PPD treats TB,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169882,7/17/2014 13:03:07,,1325257587,7/17/2014 13:02:38,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,TB treats PPD,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169882,7/17/2014 13:20:59,,1325272699,7/17/2014 13:20:16,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169882,7/17/2014 13:34:52,,1325287609,7/17/2014 13:34:36,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169882,7/17/2014 13:51:37,,1325302531,7/17/2014 13:51:10,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,PPD treats TB,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169882,7/17/2014 14:01:09,,1325311858,7/17/2014 14:00:57,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,PPD treats TB,3,22,,4,25,treats,0.361157559257307,906829-FS1-2,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169883,7/17/2014 10:31:33,,1325139283,7/17/2014 10:31:19,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,RENAL ARTERIES is location of FIBROMUSCULAR DYSPLASIA,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169883,7/17/2014 10:42:21,,1325147821,7/17/2014 10:42:07,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,RENAL ARTERIES is location of FIBROMUSCULAR DYSPLASIA,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169883,7/17/2014 11:22:52,,1325179038,7/17/2014 11:22:29,prodege,0.5754,27934334,GBR,"","",86.130.153.15,RENAL ARTERIES is location of FIBROMUSCULAR DYSPLASIA,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169883,7/17/2014 12:56:10,,1325251546,7/17/2014 12:55:46,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169883,7/17/2014 13:02:37,,1325257195,7/17/2014 13:02:10,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,RENAL ARTERIES is location of FIBROMUSCULAR DYSPLASIA,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169883,7/17/2014 13:24:52,,1325276279,7/17/2014 13:24:22,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169883,7/17/2014 13:56:01,,1325306737,7/17/2014 13:55:30,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,48,17,,61,40,is location of,0.986393923832143,905441-FS1-9,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA,RO-has_finding_site
504169884,7/17/2014 10:26:11,,1325134775,7/17/2014 10:25:52,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169884,7/17/2014 12:56:40,,1325251896,7/17/2014 12:56:11,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169884,7/17/2014 13:07:07,,1325261123,7/17/2014 13:06:33,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,NEUROFIBROMATOSIS TYPE 2 is location of SPORADIC MENINGIOMA,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169884,7/17/2014 13:22:57,,1325274519,7/17/2014 13:22:29,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169884,7/17/2014 13:33:29,,1325286407,7/17/2014 13:33:08,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,SPORADIC MENINGIOMA is location of NEUROFIBROMATOSIS TYPE 2,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169884,7/17/2014 14:01:40,,1325312492,7/17/2014 14:01:19,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169884,7/17/2014 14:03:55,,1325314551,7/17/2014 14:03:32,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,NEUROFIBROMATOSIS TYPE 2 is location of SPORADIC MENINGIOMA,101,62,,119,86,is location of,0.339683110243379,906483-FS1-9,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169885,7/17/2014 10:29:37,,1325137557,7/17/2014 10:29:06,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,SSPE BRAIN TISSUES is location of BRAIN,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169885,7/17/2014 11:08:14,,1325167425,7/17/2014 11:07:54,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,BRAIN is location of SSPE BRAIN TISSUES,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169885,7/17/2014 11:24:42,,1325180302,7/17/2014 11:23:56,prodege,0.5754,27934334,GBR,"","",86.130.153.15,BRAIN is location of SSPE BRAIN TISSUES,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169885,7/17/2014 12:10:07,,1325214343,7/17/2014 12:09:27,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,BRAIN is location of SSPE BRAIN TISSUES,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169885,7/17/2014 12:10:53,,1325214900,7/17/2014 12:10:34,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,BRAIN is location of SSPE BRAIN TISSUES,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169885,7/17/2014 13:08:09,,1325261980,7/17/2014 13:07:47,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,BRAIN is location of SSPE BRAIN TISSUES,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169885,7/17/2014 13:25:25,,1325276771,7/17/2014 13:24:53,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,205,200,,209,218,is location of,0.911684611677103,902239-FS1-9,"Moreover, the formation of large nuclear inclusions filled with smooth filaments appears to be a characteristic process of SSPE, but not of measles, since this type of inclusion is invariably seen in SSPE BRAIN TISSUES BRAIN cultures derived from them, and CV 1 cells infected with SSPE viruses.",BRAIN,SSPE BRAIN TISSUES,RO-disease_has_primary_anatomic_site
504169886,7/17/2014 10:32:10,,1325139802,7/17/2014 10:32:00,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,GLUCAGON diagnosed by INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169886,7/17/2014 10:42:18,,1325147796,7/17/2014 10:41:58,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,no_relation,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169886,7/17/2014 11:09:12,,1325168077,7/17/2014 11:09:05,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,INSULIN INDUCED HYPOGLYCEMIA diagnosed by GLUCAGON,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169886,7/17/2014 11:26:26,,1325181461,7/17/2014 11:25:53,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169886,7/17/2014 11:34:35,,1325188702,7/17/2014 11:34:11,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169886,7/17/2014 12:00:15,,1325207004,7/17/2014 11:59:45,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,INSULIN INDUCED HYPOGLYCEMIA diagnosed by GLUCAGON,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169886,7/17/2014 12:26:11,,1325226713,7/17/2014 12:25:48,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,INSULIN INDUCED HYPOGLYCEMIA diagnosed by GLUCAGON,45,4,,72,12,diagnosed by,0.377964473009227,908243-FS1-13,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169887,7/17/2014 10:32:23,,1325139978,7/17/2014 10:32:17,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,BLEPHARITIS is location of EYELID,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169887,7/17/2014 10:35:24,,1325142634,7/17/2014 10:34:55,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,EYELID is location of BLEPHARITIS,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169887,7/17/2014 11:14:32,,1325172671,7/17/2014 11:14:16,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169887,7/17/2014 11:28:57,,1325183269,7/17/2014 11:28:12,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,EYELID is location of BLEPHARITIS,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169887,7/17/2014 11:30:32,,1325184721,7/17/2014 11:30:19,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,EYELID is location of BLEPHARITIS,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169887,7/17/2014 12:28:24,,1325228628,7/17/2014 12:28:13,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,EYELID is location of BLEPHARITIS,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169887,7/17/2014 12:57:24,,1325252421,7/17/2014 12:57:16,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,EYELID is location of BLEPHARITIS,257,194,,262,205,is location of,0.78086880944303,905409-FS1-9,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169888,7/17/2014 11:09:05,,1325168015,7/17/2014 11:08:54,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,CHOLECYSTITIS causes GALLBLADDER METASTASIS,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169888,7/17/2014 11:29:13,,1325183396,7/17/2014 11:28:33,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169888,7/17/2014 11:45:15,,1325196669,7/17/2014 11:44:53,instagc,0.6489,13763729,USA,"","",75.182.89.225,CHOLECYSTITIS causes GALLBLADDER METASTASIS,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169888,7/17/2014 12:01:08,,1325207657,7/17/2014 12:00:48,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,GALLBLADDER METASTASIS causes CHOLECYSTITIS,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169888,7/17/2014 12:55:16,,1325250849,7/17/2014 12:54:58,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,CHOLECYSTITIS causes GALLBLADDER METASTASIS,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169888,7/17/2014 13:08:38,,1325262315,7/17/2014 13:08:11,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,CHOLECYSTITIS causes GALLBLADDER METASTASIS,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169888,7/17/2014 13:56:29,,1325307150,7/17/2014 13:56:03,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,CHOLECYSTITIS causes GALLBLADDER METASTASIS,102,187,,123,200,causes,0.963086824686154,905346-FS1-4,The two reported cases and the 18 cases from the literature indicate that the physician must consider GALLBLADDER METASTASIS in melanoma patients presenting with symptoms compatible with CHOLECYSTITIS,GALLBLADDER METASTASIS,CHOLECYSTITIS,RO-has_finding_site
504169889,7/17/2014 10:39:44,,1325145842,7/17/2014 10:39:19,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,ANXIETY causes OBSESSIVE COMPULSIVE NEUROSIS,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169889,7/17/2014 10:41:19,,1325147100,7/17/2014 10:40:53,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,OBSESSIVE COMPULSIVE NEUROSIS causes ANXIETY,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169889,7/17/2014 11:07:52,,1325167081,7/17/2014 11:07:42,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,OBSESSIVE COMPULSIVE NEUROSIS causes ANXIETY,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169889,7/17/2014 11:34:10,,1325188225,7/17/2014 11:33:43,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,ANXIETY causes OBSESSIVE COMPULSIVE NEUROSIS,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169889,7/17/2014 11:50:58,,1325200854,7/17/2014 11:50:32,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169889,7/17/2014 11:58:36,,1325205932,7/17/2014 11:58:15,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169889,7/17/2014 12:29:20,,1325229410,7/17/2014 12:28:52,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,OBSESSIVE COMPULSIVE NEUROSIS causes ANXIETY,79,106,,85,135,causes,0.78086880944303,904918-FS1-4,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169890,7/17/2014 10:33:40,,1325141082,7/17/2014 10:33:17,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169890,7/17/2014 11:30:35,,1325184741,7/17/2014 11:29:43,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169890,7/17/2014 12:25:05,,1325225930,7/17/2014 12:24:37,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169890,7/17/2014 12:54:55,,1325250530,7/17/2014 12:54:45,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169890,7/17/2014 13:37:53,,1325290042,7/17/2014 13:37:18,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169890,7/17/2014 13:55:29,,1325306204,7/17/2014 13:54:55,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169890,7/17/2014 14:00:56,,1325311635,7/17/2014 14:00:42,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,BEPRIDIL treats ANGINA,139,191,,144,199,treats,0.883452208598772,908351-FS1-2,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169891,7/17/2014 10:31:08,,1325138818,7/17/2014 10:31:02,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169891,7/17/2014 10:44:38,,1325149625,7/17/2014 10:44:14,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169891,7/17/2014 11:09:42,,1325168567,7/17/2014 11:09:33,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169891,7/17/2014 11:15:07,,1325173141,7/17/2014 11:14:52,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169891,7/17/2014 11:29:14,,1325183420,7/17/2014 11:28:23,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169891,7/17/2014 11:30:54,,1325184992,7/17/2014 11:30:22,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169891,7/17/2014 13:02:37,,1325257197,7/17/2014 13:02:10,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,NEOSTIGMINE treats MYASTHENIA GRAVIS,23,84,,39,95,treats,1,906775-FS1-2,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
504169892,7/17/2014 10:30:46,,1325138508,7/17/2014 10:30:17,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,SEGMENTAL BRONCHI is location of BRONCHIECTASIS,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169892,7/17/2014 10:35:24,,1325142617,7/17/2014 10:35:17,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169892,7/17/2014 10:40:00,,1325146056,7/17/2014 10:39:44,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,SEGMENTAL BRONCHI is location of BRONCHIECTASIS,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169892,7/17/2014 11:30:35,,1325184743,7/17/2014 11:29:43,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,SEGMENTAL BRONCHI is location of BRONCHIECTASIS,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169892,7/17/2014 11:46:11,,1325197384,7/17/2014 11:45:48,instagc,0.6489,13763729,USA,"","",75.182.89.225,SEGMENTAL BRONCHI is location of BRONCHIECTASIS,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169892,7/17/2014 11:55:20,,1325203700,7/17/2014 11:55:04,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169892,7/17/2014 13:05:29,,1325259816,7/17/2014 13:04:56,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,BRONCHIECTASIS is location of SEGMENTAL BRONCHI,11,94,,27,108,is location of,0.744208407535251,905364-FS1-9,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169893,7/17/2014 10:30:44,,1325138496,7/17/2014 10:30:38,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,DPA INDUCED CICATRICIAL PEMPHIGOID causes MUCOUS AND CUTANEOUS INVOLVEMENT,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169893,7/17/2014 10:45:00,,1325149960,7/17/2014 10:44:39,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169893,7/17/2014 11:22:28,,1325178771,7/17/2014 11:22:05,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169893,7/17/2014 11:27:28,,1325182141,7/17/2014 11:26:56,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169893,7/17/2014 11:49:14,,1325199681,7/17/2014 11:48:28,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169893,7/17/2014 13:03:30,,1325257912,7/17/2014 13:03:08,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,MUCOUS AND CUTANEOUS INVOLVEMENT causes DPA INDUCED CICATRICIAL PEMPHIGOID,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169893,7/17/2014 13:35:32,,1325288186,7/17/2014 13:35:14,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,63,0,,94,34,causes,0.768221279597376,901974-FS1-4,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169894,7/17/2014 10:34:54,,1325142088,7/17/2014 10:34:23,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,TESTICULAR GERM CELL CANCER is location of CONTRALATERAL TESTIS,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169894,7/17/2014 10:45:47,,1325150572,7/17/2014 10:45:22,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,CONTRALATERAL TESTIS is location of TESTICULAR GERM CELL CANCER,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169894,7/17/2014 11:29:47,,1325184026,7/17/2014 11:29:15,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169894,7/17/2014 12:23:16,,1325224601,7/17/2014 12:22:48,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,CONTRALATERAL TESTIS is location of TESTICULAR GERM CELL CANCER,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169894,7/17/2014 13:07:46,,1325261600,7/17/2014 13:07:08,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,TESTICULAR GERM CELL CANCER is location of CONTRALATERAL TESTIS,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169894,7/17/2014 13:16:26,,1325268741,7/17/2014 13:15:35,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,CONTRALATERAL TESTIS is location of TESTICULAR GERM CELL CANCER,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169894,7/17/2014 13:20:56,,1325272659,7/17/2014 13:20:26,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,CONTRALATERAL TESTIS is location of TESTICULAR GERM CELL CANCER,20,68,,39,95,is location of,0.888888888888889,902445-FS1-9,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169895,7/17/2014 10:21:25,,1325131254,7/17/2014 10:21:18,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,MEN2A diagnosed by PRIMARY HYPERPARATHYROIDISM,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169895,7/17/2014 10:32:16,,1325139893,7/17/2014 10:32:11,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,MEN2A diagnosed by PRIMARY HYPERPARATHYROIDISM,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169895,7/17/2014 11:08:14,,1325167424,7/17/2014 11:07:54,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,PRIMARY HYPERPARATHYROIDISM diagnosed by MEN2A,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169895,7/17/2014 11:26:26,,1325181462,7/17/2014 11:25:53,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169895,7/17/2014 11:33:36,,1325187686,7/17/2014 11:33:04,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,PRIMARY HYPERPARATHYROIDISM diagnosed by MEN2A,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169895,7/17/2014 13:35:53,,1325288383,7/17/2014 13:35:34,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169895,7/17/2014 13:51:59,,1325302963,7/17/2014 13:51:39,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,62,139,,88,144,diagnosed by,0.358568582800318,906333-FS1-13,? Data from cohort studies of patients with MEN2a reveal that PRIMARY HYPERPARATHYROIDISM is present in approximately 30% of patients with MEN2A.,PRIMARY HYPERPARATHYROIDISM,MEN2A,RO-has_manifestation
504169896,7/17/2014 11:13:38,,1325171992,7/17/2014 11:13:12,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,INTRACORPOREAL PAPAVERINE diagnosed by ERECTILE DYSFUNCTION,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169896,7/17/2014 11:31:15,,1325185279,7/17/2014 11:30:37,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,ERECTILE DYSFUNCTION diagnosed by INTRACORPOREAL PAPAVERINE,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169896,7/17/2014 11:49:41,,1325199973,7/17/2014 11:49:15,instagc,0.6489,13763729,USA,"","",75.182.89.225,ERECTILE DYSFUNCTION diagnosed by INTRACORPOREAL PAPAVERINE,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169896,7/17/2014 12:25:29,,1325226299,7/17/2014 12:25:06,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,INTRACORPOREAL PAPAVERINE diagnosed by ERECTILE DYSFUNCTION,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169896,7/17/2014 13:20:15,,1325272142,7/17/2014 13:19:35,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,ERECTILE DYSFUNCTION diagnosed by INTRACORPOREAL PAPAVERINE,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169896,7/17/2014 13:52:38,,1325303587,7/17/2014 13:52:00,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,ERECTILE DYSFUNCTION diagnosed by INTRACORPOREAL PAPAVERINE,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169896,7/17/2014 14:02:16,,1325313070,7/17/2014 14:02:04,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,ERECTILE DYSFUNCTION diagnosed by INTRACORPOREAL PAPAVERINE,82,0,,101,25,diagnosed by,0.997458699830735,906591-FS1-13,INTRACORPOREAL PAPAVERINE has been used as an out patient procedure to assess the ERECTILE DYSFUNCTION of 129 men.,ERECTILE DYSFUNCTION,INTRACORPOREAL PAPAVERINE,RO-may_diagnose
504169897,7/17/2014 10:39:18,,1325145471,7/17/2014 10:38:57,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,EMESIS diagnosed by ONDANSETRON,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169897,7/17/2014 11:08:57,,1325167926,7/17/2014 11:08:34,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,EMESIS diagnosed by ONDANSETRON,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169897,7/17/2014 11:25:47,,1325180990,7/17/2014 11:25:19,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,EMESIS diagnosed by ONDANSETRON,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169897,7/17/2014 11:31:55,,1325185931,7/17/2014 11:31:29,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,EMESIS diagnosed by ONDANSETRON,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169897,7/17/2014 12:12:13,,1325216046,7/17/2014 12:11:49,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169897,7/17/2014 12:57:24,,1325252420,7/17/2014 12:57:16,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169897,7/17/2014 13:20:59,,1325272700,7/17/2014 13:20:16,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,23,46,,28,57,diagnosed by,0.881917103688197,907449-FS1-13,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON,RO-may_prevent
504169898,7/17/2014 10:32:04,,1325139731,7/17/2014 10:31:34,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,OHSS causes ASCITES,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169898,7/17/2014 10:42:18,,1325147813,7/17/2014 10:41:58,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,OHSS causes ASCITES,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169898,7/17/2014 10:45:20,,1325150143,7/17/2014 10:45:01,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169898,7/17/2014 11:08:54,,1325167904,7/17/2014 11:08:45,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,OHSS causes ASCITES,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169898,7/17/2014 11:13:57,,1325172218,7/17/2014 11:13:40,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169898,7/17/2014 11:29:48,,1325184038,7/17/2014 11:29:17,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169898,7/17/2014 11:48:27,,1325198964,7/17/2014 11:48:03,instagc,0.6489,13763729,USA,"","",75.182.89.225,OHSS causes ASCITES,89,42,,95,46,causes,0.797724035217466,906261-FS1-4,"Other physical and laboratory findings of OHSS include weight gain, ovarian enlargement, ASCITES pleural effusion, hemoconcentration, electrolyte imbalances, renal dysfunction, and thrombosis.",ASCITES,OHSS,RO-has_manifestation
504169899,7/17/2014 11:27:47,,1325182429,7/17/2014 11:27:29,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169899,7/17/2014 11:35:16,,1325189290,7/17/2014 11:35:02,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169899,7/17/2014 11:50:58,,1325200855,7/17/2014 11:50:32,instagc,0.6489,13763729,USA,"","",75.182.89.225,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169899,7/17/2014 11:59:05,,1325206383,7/17/2014 11:58:53,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169899,7/17/2014 12:07:08,,1325212059,7/17/2014 12:06:52,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169899,7/17/2014 12:26:11,,1325226724,7/17/2014 12:25:48,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169899,7/17/2014 12:54:16,,1325250007,7/17/2014 12:54:04,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,77,45,,101,56,treats,1,907639-FS1-2,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN,RO-may_treat
504169900,7/17/2014 10:31:01,,1325138775,7/17/2014 10:30:54,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,BRONCHIAL HYPERREACTIVITY treats METHACHOLINE,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169900,7/17/2014 11:14:14,,1325172424,7/17/2014 11:13:58,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169900,7/17/2014 11:31:01,,1325185094,7/17/2014 11:30:49,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169900,7/17/2014 11:58:36,,1325205958,7/17/2014 11:58:15,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169900,7/17/2014 12:25:47,,1325226423,7/17/2014 12:25:30,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169900,7/17/2014 12:56:49,,1325251976,7/17/2014 12:56:41,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169900,7/17/2014 13:01:53,,1325256483,7/17/2014 13:01:37,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,225,266,,249,278,treats,0.693375245281537,906530-FS1-2,"We found that genetically mast cell deficient WBB6F(1) W/W(v) mice that were sensitized to ovalbumin (OVA) without adjuvant, then challenged repetitively with antigen intranasally, exhibited much weaker responses in terms of BRONCHIAL HYPERREACTIVITY to aerosolized METHACHOLINE lung tissue eosinophil infiltration, and numbers of proliferating cells within the airway epithelium than did identically treated WBB6F(1) +/+ normal mice.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
504169901,7/17/2014 10:31:30,,1325139234,7/17/2014 10:31:25,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169901,7/17/2014 10:34:46,,1325141991,7/17/2014 10:34:39,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169901,7/17/2014 11:02:20,,1325163111,7/17/2014 11:01:54,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169901,7/17/2014 11:47:37,,1325198343,7/17/2014 11:47:07,instagc,0.6489,13763729,USA,"","",75.182.89.225,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169901,7/17/2014 11:57:39,,1325205223,7/17/2014 11:57:12,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169901,7/17/2014 12:10:36,,1325214667,7/17/2014 12:10:21,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169901,7/17/2014 13:20:56,,1325272654,7/17/2014 13:20:26,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,62,26,,84,40,treats,0.964901281354015,907508-FS1-2,Fluconazole compared with AMPHOTERICIN B plus flucytosine for CRYPTOCOCCAL MENINGITIS in AIDS: a randomized trial.,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B,RO-may_treat
504169902,7/17/2014 10:22:05,,1325131755,7/17/2014 10:21:55,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,COLON CANCER causes FAMILIAL ADENOMATOUS POLYPOSIS,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169902,7/17/2014 10:33:16,,1325140705,7/17/2014 10:32:34,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169902,7/17/2014 11:25:17,,1325180687,7/17/2014 11:24:52,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169902,7/17/2014 11:31:28,,1325185537,7/17/2014 11:30:56,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169902,7/17/2014 11:46:43,,1325197735,7/17/2014 11:46:11,instagc,0.6489,13763729,USA,"","",75.182.89.225,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169902,7/17/2014 12:08:11,,1325212776,7/17/2014 12:07:35,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169902,7/17/2014 13:54:31,,1325305497,7/17/2014 13:53:59,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,48,74,,59,104,causes,0.58925565098879,906092-FS1-4,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS,RO-has_manifestation
504169903,7/17/2014 10:41:57,,1325147541,7/17/2014 10:41:45,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,OSTEOPOROSIS causes BONE CELLS,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169903,7/17/2014 11:27:39,,1325182294,7/17/2014 11:26:28,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169903,7/17/2014 11:28:57,,1325183246,7/17/2014 11:28:12,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,no_relation,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169903,7/17/2014 13:15:34,,1325268051,7/17/2014 13:14:39,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,OSTEOPOROSIS causes BONE CELLS,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169903,7/17/2014 13:53:59,,1325305086,7/17/2014 13:53:28,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169903,7/17/2014 14:00:56,,1325311636,7/17/2014 14:00:42,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,BONE CELLS causes OSTEOPOROSIS,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169903,7/17/2014 14:03:32,,1325314191,7/17/2014 14:03:11,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,BONE CELLS causes OSTEOPOROSIS,112,170,,121,182,causes,0.529812942826018,902076-FS1-4,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169904,7/17/2014 10:21:25,,1325131259,7/17/2014 10:21:18,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169904,7/17/2014 10:35:24,,1325142633,7/17/2014 10:34:55,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169904,7/17/2014 10:42:52,,1325148255,7/17/2014 10:42:19,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,HEPATOMA causes ASCITES,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169904,7/17/2014 11:13:11,,1325171587,7/17/2014 11:12:34,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,ASCITES causes HEPATOMA,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169904,7/17/2014 11:28:07,,1325182612,7/17/2014 11:27:49,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169904,7/17/2014 11:46:11,,1325197382,7/17/2014 11:45:48,instagc,0.6489,13763729,USA,"","",75.182.89.225,ASCITES causes HEPATOMA,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169904,7/17/2014 12:54:55,,1325250531,7/17/2014 12:54:45,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,4,52,,10,60,causes,0.492365963917331,902866-FS1-4,"The ASCITES form of a chemically induced guinea pig HEPATOMA line 10, was resistant to killing in vitro by xenogeneic antibody and guinea pig complement.",ASCITES,HEPATOMA,RO-disease_may_have_finding
504169905,7/17/2014 10:30:46,,1325138504,7/17/2014 10:30:17,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169905,7/17/2014 10:31:16,,1325138939,7/17/2014 10:31:10,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169905,7/17/2014 10:34:03,,1325141407,7/17/2014 10:33:57,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169905,7/17/2014 10:41:19,,1325147099,7/17/2014 10:40:53,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169905,7/17/2014 11:29:14,,1325183432,7/17/2014 11:28:23,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169905,7/17/2014 11:58:53,,1325206174,7/17/2014 11:58:37,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,WITH DYSPROTEINEMIA (AILD) causes LYMPHADENOPATHY,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169905,7/17/2014 12:57:35,,1325252610,7/17/2014 12:57:25,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,126,35,,140,61,causes,0.968495996958186,902569-FS1-4,"Angioimmunoblastic lymphadenopathy WITH DYSPROTEINEMIA (AILD) is a rare lymphoproliferative disorder characterized by diffuse LYMPHADENOPATHY fever, hepatosplenomegaly, hemolytic anemia, and polyclonal hypergammaglobulinemia.",LYMPHADENOPATHY,WITH DYSPROTEINEMIA (AILD),RO-disease_may_have_finding
504169906,7/17/2014 10:39:44,,1325145837,7/17/2014 10:39:19,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,TUBERCULOSIS diagnosed by TUBERCULIN,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169906,7/17/2014 11:06:36,,1325166033,7/17/2014 11:06:07,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,TUBERCULOSIS diagnosed by TUBERCULIN,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169906,7/17/2014 11:07:42,,1325166928,7/17/2014 11:07:28,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,TUBERCULOSIS diagnosed by TUBERCULIN,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169906,7/17/2014 11:28:32,,1325182932,7/17/2014 11:27:40,prodege,0.5754,27934334,GBR,"","",86.130.153.15,TUBERCULIN diagnosed by TUBERCULOSIS,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169906,7/17/2014 11:33:03,,1325187158,7/17/2014 11:32:18,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,TUBERCULIN diagnosed by TUBERCULOSIS,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169906,7/17/2014 12:09:25,,1325213673,7/17/2014 12:08:53,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,TUBERCULOSIS diagnosed by TUBERCULIN,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169906,7/17/2014 12:25:05,,1325225933,7/17/2014 12:24:37,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,TUBERCULOSIS diagnosed by TUBERCULIN,130,51,,141,61,diagnosed by,0.976092160357725,906619-FS1-13,"Current diagnostic tests for tuberculosis based on TUBERCULIN have poor specificity, and both BCG vaccination and exposure to non TUBERCULOSIS mycobacteria produce a response similar to that induced by infection with Mycobacterium tuberculosis.",TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
504169907,7/17/2014 10:22:05,,1325131756,7/17/2014 10:21:55,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169907,7/17/2014 10:40:19,,1325146322,7/17/2014 10:40:01,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,CLL causes LYMPHADENOPATHY,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169907,7/17/2014 11:06:45,,1325166209,7/17/2014 11:06:29,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,LYMPHADENOPATHY causes CLL,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169907,7/17/2014 11:20:33,,1325177248,7/17/2014 11:19:51,prodege,0.5754,27934334,GBR,"","",86.130.153.15,CLL causes LYMPHADENOPATHY,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169907,7/17/2014 11:33:24,,1325187544,7/17/2014 11:32:32,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,CLL causes LYMPHADENOPATHY,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169907,7/17/2014 12:07:34,,1325212410,7/17/2014 12:07:09,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,LYMPHADENOPATHY causes CLL,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169907,7/17/2014 13:23:08,,1325274654,7/17/2014 13:22:35,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,82,131,,96,134,causes,0.339683110243379,902686-FS1-4,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169908,7/17/2014 10:32:23,,1325139977,7/17/2014 10:32:17,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,CANCER OF THE CERVIX causes UTERINE CERVIX,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169908,7/17/2014 11:04:16,,1325164409,7/17/2014 11:03:43,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169908,7/17/2014 11:20:33,,1325177245,7/17/2014 11:19:51,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169908,7/17/2014 11:30:48,,1325184867,7/17/2014 11:30:33,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169908,7/17/2014 12:10:53,,1325214896,7/17/2014 12:10:34,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,UTERINE CERVIX causes CANCER OF THE CERVIX,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169908,7/17/2014 13:34:35,,1325287386,7/17/2014 13:34:12,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169908,7/17/2014 13:53:27,,1325304516,7/17/2014 13:53:09,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,28,115,,41,135,causes,0.303045763365663,902354-FS1-4,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 10:39:18,,1325145469,7/17/2014 10:38:57,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,HASHIMOTO'S THYROIDITIS causes THYROID,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 11:13:38,,1325171995,7/17/2014 11:13:12,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 11:33:42,,1325187788,7/17/2014 11:33:26,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,THYROID causes HASHIMOTO'S THYROIDITIS,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 13:04:27,,1325258896,7/17/2014 13:03:55,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,no_relation,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 13:32:17,,1325285348,7/17/2014 13:31:55,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 13:56:58,,1325307700,7/17/2014 13:56:30,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169909,7/17/2014 14:00:41,,1325311363,7/17/2014 14:00:26,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,28,16,,34,39,causes,0.341743063086704,902140-FS1-4,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169910,7/17/2014 10:21:33,,1325131352,7/17/2014 10:21:26,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169910,7/17/2014 10:32:29,,1325140025,7/17/2014 10:32:24,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,DPA INDUCED CICATRICIAL PEMPHIGOID is location of MUCOUS AND CUTANEOUS INVOLVEMENT,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169910,7/17/2014 10:44:38,,1325149621,7/17/2014 10:44:14,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,DPA INDUCED CICATRICIAL PEMPHIGOID is location of MUCOUS AND CUTANEOUS INVOLVEMENT,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169910,7/17/2014 11:05:37,,1325165354,7/17/2014 11:05:11,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,MUCOUS AND CUTANEOUS INVOLVEMENT is location of DPA INDUCED CICATRICIAL PEMPHIGOID,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169910,7/17/2014 11:06:29,,1325165960,7/17/2014 11:06:07,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,MUCOUS AND CUTANEOUS INVOLVEMENT is location of DPA INDUCED CICATRICIAL PEMPHIGOID,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169910,7/17/2014 11:19:13,,1325176379,7/17/2014 11:18:57,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169910,7/17/2014 11:21:21,,1325177923,7/17/2014 11:20:34,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,63,0,,94,34,is location of,0.384110639798688,901974-FS1-9,DPA INDUCED CICATRICIAL PEMPHIGOID is a severe disease of both MUCOUS AND CUTANEOUS INVOLVEMENT with a prognosis similar to the spontaneous disease.,MUCOUS AND CUTANEOUS INVOLVEMENT,DPA INDUCED CICATRICIAL PEMPHIGOID,RO-disease_has_finding
504169911,7/17/2014 10:31:30,,1325139233,7/17/2014 10:31:25,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,LYME DISEASE causes SPIROCHETE BORRELIA BURGDORFERI,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169911,7/17/2014 10:43:17,,1325148626,7/17/2014 10:42:53,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169911,7/17/2014 11:09:24,,1325168260,7/17/2014 11:09:13,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169911,7/17/2014 11:11:04,,1325169646,7/17/2014 11:10:44,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169911,7/17/2014 11:19:13,,1325176405,7/17/2014 11:18:57,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169911,7/17/2014 11:24:42,,1325180301,7/17/2014 11:23:56,prodege,0.5754,27934334,GBR,"","",86.130.153.15,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169911,7/17/2014 12:26:57,,1325227326,7/17/2014 12:26:42,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,4,62,,34,74,causes,1,903501-FS1-4,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE,RO-has_causative_agent
504169912,7/17/2014 11:07:07,,1325166398,7/17/2014 11:06:45,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,SEVERE DYSPLASIA causes CARCINOMA IN SITU,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169912,7/17/2014 12:11:47,,1325215796,7/17/2014 12:11:28,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,SEVERE DYSPLASIA causes CARCINOMA IN SITU,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169912,7/17/2014 13:19:33,,1325271509,7/17/2014 13:18:45,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169912,7/17/2014 13:34:11,,1325287096,7/17/2014 13:33:50,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169912,7/17/2014 13:57:18,,1325307974,7/17/2014 13:56:59,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169912,7/17/2014 14:03:20,,1325314066,7/17/2014 14:03:07,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,CARCINOMA IN SITU causes SEVERE DYSPLASIA,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169912,7/17/2014 14:03:55,,1325314553,7/17/2014 14:03:32,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,CARCINOMA IN SITU causes SEVERE DYSPLASIA,165,78,,180,95,causes,0.50709255283711,901932-FS1-4,"Only two premalignant lesions showed absence of p16 expression, of which one (CARCINOMA IN SITU was hypermethylated at the p16(INK4a) promoter region and the other (SEVERE DYSPLASIA showed BMI 1 expression.",SEVERE DYSPLASIA,CARCINOMA IN SITU,RO-disease_has_finding
504169913,7/17/2014 10:35:24,,1325142616,7/17/2014 10:35:17,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,BONE CELLS is location of OSTEOPOROSIS,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169913,7/17/2014 10:42:37,,1325148052,7/17/2014 10:42:22,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,BONE CELLS is location of OSTEOPOROSIS,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169913,7/17/2014 11:16:14,,1325173985,7/17/2014 11:15:47,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169913,7/17/2014 11:29:31,,1325183752,7/17/2014 11:29:16,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,BONE CELLS is location of OSTEOPOROSIS,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169913,7/17/2014 11:56:37,,1325204544,7/17/2014 11:56:17,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,BONE CELLS is location of OSTEOPOROSIS,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169913,7/17/2014 12:11:09,,1325215224,7/17/2014 12:10:55,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,BONE CELLS is location of OSTEOPOROSIS,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169913,7/17/2014 12:11:48,,1325215797,7/17/2014 12:11:30,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,BONE CELLS is location of OSTEOPOROSIS,112,170,,121,182,is location of,0.794719414239026,902076-FS1-9,"Interleukin 6 (IL 6) is an attractive candidate gene for osteoporosis susceptibility, because it has effects on BONE CELLS and has been implicated in the pathogenesis of OSTEOPOROSIS",BONE CELLS,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
504169914,7/17/2014 10:32:10,,1325139804,7/17/2014 10:32:00,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,ANTIARRHYTHMIC causes ARRHYTHMIA,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169914,7/17/2014 11:09:58,,1325168774,7/17/2014 11:09:34,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,ANTIARRHYTHMIC causes ARRHYTHMIA,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169914,7/17/2014 11:35:01,,1325189029,7/17/2014 11:34:35,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,ARRHYTHMIA causes ANTIARRHYTHMIC,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169914,7/17/2014 11:59:45,,1325206733,7/17/2014 11:59:27,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169914,7/17/2014 12:11:07,,1325215147,7/17/2014 12:10:36,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169914,7/17/2014 12:29:20,,1325229408,7/17/2014 12:28:52,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169914,7/17/2014 12:57:14,,1325252326,7/17/2014 12:57:07,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,79,169,,88,183,causes,0.496138938356834,907386-FS1-4,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169915,7/17/2014 10:41:11,,1325146971,7/17/2014 10:40:47,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169915,7/17/2014 11:14:32,,1325172646,7/17/2014 11:14:16,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169915,7/17/2014 11:21:21,,1325177924,7/17/2014 11:20:34,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169915,7/17/2014 11:28:07,,1325182626,7/17/2014 11:27:49,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169915,7/17/2014 11:29:16,,1325183470,7/17/2014 11:28:41,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169915,7/17/2014 12:10:33,,1325214641,7/17/2014 12:10:14,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169915,7/17/2014 12:24:36,,1325225460,7/17/2014 12:24:06,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,ACETYLSALICYLIC ACID treats MYOCARDIAL INFARCTION,189,214,,209,234,treats,0.997458699830735,907247-FS1-2,"Remarkable examples are arteriosclerosis and its complications, where the role of thromboxane and prostacyclin was discovered and led to the development of strategies for the prevention of MYOCARDIAL INFARCTION by ACETYLSALICYLIC ACID",MYOCARDIAL INFARCTION,ACETYLSALICYLIC ACID,RO-may_prevent
504169916,7/17/2014 10:29:55,,1325137856,7/17/2014 10:29:38,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169916,7/17/2014 10:35:04,,1325142278,7/17/2014 10:34:57,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169916,7/17/2014 10:41:44,,1325147402,7/17/2014 10:41:12,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,ANTIGENIC PROPERTIES OF SKIN diagnosed by SKIN SPECIFIC PEMPHIGUS VULGARIS,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169916,7/17/2014 11:09:58,,1325168775,7/17/2014 11:09:34,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,SKIN SPECIFIC PEMPHIGUS VULGARIS diagnosed by ANTIGENIC PROPERTIES OF SKIN,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169916,7/17/2014 11:33:24,,1325187545,7/17/2014 11:32:32,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,ANTIGENIC PROPERTIES OF SKIN diagnosed by SKIN SPECIFIC PEMPHIGUS VULGARIS,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169916,7/17/2014 13:03:07,,1325257589,7/17/2014 13:02:38,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,SKIN SPECIFIC PEMPHIGUS VULGARIS diagnosed by ANTIGENIC PROPERTIES OF SKIN,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169916,7/17/2014 13:23:08,,1325274659,7/17/2014 13:22:35,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,ANTIGENIC PROPERTIES OF SKIN diagnosed by SKIN SPECIFIC PEMPHIGUS VULGARIS,109,188,,136,220,diagnosed by,0.645497224367903,902125-FS1-13,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
504169917,7/17/2014 10:21:44,,1325131509,7/17/2014 10:21:34,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,CUSHING'S SYNDROME causes EXOGENOUS DEXAMETHASONE,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169917,7/17/2014 11:09:33,,1325168425,7/17/2014 11:08:58,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,CUSHING'S SYNDROME causes EXOGENOUS DEXAMETHASONE,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169917,7/17/2014 11:29:47,,1325184019,7/17/2014 11:29:15,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169917,7/17/2014 11:31:19,,1325185326,7/17/2014 11:31:02,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169917,7/17/2014 12:00:48,,1325207378,7/17/2014 12:00:16,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169917,7/17/2014 13:02:24,,1325256949,7/17/2014 13:01:55,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169917,7/17/2014 13:58:30,,1325309279,7/17/2014 13:58:04,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,33,52,,50,75,causes,0.755928946018454,906695-FS1-4,"However, in 75% of the dogs with CUSHING'S SYNDROME EXOGENOUS DEXAMETHASONE was cleared completely in the 3 hour test.",CUSHING'S SYNDROME,EXOGENOUS DEXAMETHASONE,RO-may_diagnose
504169918,7/17/2014 11:08:27,,1325167603,7/17/2014 11:08:16,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169918,7/17/2014 11:56:16,,1325204369,7/17/2014 11:55:52,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169918,7/17/2014 12:12:41,,1325216446,7/17/2014 12:11:48,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169918,7/17/2014 12:54:42,,1325250383,7/17/2014 12:54:32,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169918,7/17/2014 13:08:55,,1325262448,7/17/2014 13:08:39,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169918,7/17/2014 13:32:39,,1325285694,7/17/2014 13:32:18,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169918,7/17/2014 13:53:59,,1325305064,7/17/2014 13:53:28,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,GLUCAGON treats HYPOGLYCEMIA,55,100,,66,108,treats,1,907911-FS1-2,"For patients who are unconscious or unable to swallow, HYPOGLYCEMIA can be treated immediately with GLUCAGON 1 mg sc or IM or a 50% dextrose solution 50 mL IV (25 g), followed, if necessary, by IV infusion of a 5 or 10% dextrose solution to maintain adequate plasma glucose levels.",HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 10:40:19,,1325146323,7/17/2014 10:40:01,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 11:15:27,,1325173431,7/17/2014 11:15:09,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,INSULIN INDUCED HYPOGLYCEMIA treats GLUCAGON,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 11:30:18,,1325184524,7/17/2014 11:29:52,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 12:28:51,,1325229040,7/17/2014 12:28:25,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 13:08:38,,1325262316,7/17/2014 13:08:11,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 13:21:26,,1325273162,7/17/2014 13:20:57,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,GLUCAGON treats INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169919,7/17/2014 13:37:16,,1325289543,7/17/2014 13:36:52,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,45,4,,72,12,treats,0.755928946018454,908243-FS1-2,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169920,7/17/2014 10:34:13,,1325141538,7/17/2014 10:34:05,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,ACTINIC KERATOSIS treats SKIN CONDITIONS,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169920,7/17/2014 11:08:57,,1325167927,7/17/2014 11:08:34,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169920,7/17/2014 11:16:36,,1325174303,7/17/2014 11:16:15,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169920,7/17/2014 11:23:54,,1325179822,7/17/2014 11:23:23,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169920,7/17/2014 11:48:02,,1325198702,7/17/2014 11:47:39,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169920,7/17/2014 11:58:53,,1325206175,7/17/2014 11:58:37,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169920,7/17/2014 12:08:52,,1325213327,7/17/2014 12:08:35,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,66,92,,80,109,treats,0.78086880944303,902260-FS1-2,The sap of the plant Euphorbia peplus is a traditional remedy for SKIN CONDITIONS including ACTINIC KERATOSIS,SKIN CONDITIONS,ACTINIC KERATOSIS,RO-disease_has_primary_anatomic_site
504169921,7/17/2014 10:32:33,,1325140075,7/17/2014 10:32:05,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169921,7/17/2014 10:35:15,,1325142507,7/17/2014 10:35:05,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169921,7/17/2014 10:46:07,,1325150833,7/17/2014 10:45:48,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169921,7/17/2014 11:19:45,,1325176696,7/17/2014 11:19:27,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169921,7/17/2014 11:35:48,,1325189823,7/17/2014 11:35:17,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169921,7/17/2014 12:23:16,,1325224607,7/17/2014 12:22:48,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169921,7/17/2014 13:58:03,,1325308757,7/17/2014 13:57:19,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,257,194,,262,205,causes,0.468521285665818,905409-FS1-4,"However, madarosis may be the presenting sign of DLE in the absence of any history of preceding erythema and scarring and should therefore be considered in the differential diagnosis of chronic BLEPHARITIS that persists despite usual medical management and EYELID hygiene.",EYELID,BLEPHARITIS,RO-has_finding_site
504169922,7/17/2014 10:31:08,,1325138817,7/17/2014 10:31:02,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,ARRHYTHMIA treats ANTIARRHYTHMIC,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169922,7/17/2014 10:34:23,,1325141671,7/17/2014 10:33:57,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169922,7/17/2014 10:40:46,,1325146688,7/17/2014 10:40:20,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,ANTIARRHYTHMIC treats ARRHYTHMIA,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169922,7/17/2014 12:10:36,,1325214670,7/17/2014 12:10:21,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,ANTIARRHYTHMIC treats ARRHYTHMIA,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169922,7/17/2014 12:57:06,,1325252213,7/17/2014 12:56:58,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169922,7/17/2014 13:02:41,,1325257256,7/17/2014 13:02:25,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,ANTIARRHYTHMIC treats ARRHYTHMIA,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169922,7/17/2014 13:19:33,,1325271511,7/17/2014 13:18:45,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,ANTIARRHYTHMIC treats ARRHYTHMIA,79,169,,88,183,treats,0.744208407535251,907386-FS1-2,The choice of the antiarrhythmic treatment must always be based on the type of ARRHYTHMIA the presence of a structural cardiopathy and the potential side effects of the ANTIARRHYTHMIC drug.,ARRHYTHMIA,ANTIARRHYTHMIC,RO-may_prevent
504169923,7/17/2014 10:30:17,,1325138161,7/17/2014 10:29:57,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169923,7/17/2014 10:31:36,,1325139325,7/17/2014 10:31:32,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,X LINKED INFANTILE SPASMS causes SEIZURES,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169923,7/17/2014 11:50:06,,1325200223,7/17/2014 11:49:42,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169923,7/17/2014 11:59:25,,1325206567,7/17/2014 11:59:06,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,X LINKED INFANTILE SPASMS causes SEIZURES,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169923,7/17/2014 13:07:07,,1325261127,7/17/2014 13:06:33,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,X LINKED INFANTILE SPASMS causes SEIZURES,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169923,7/17/2014 13:24:21,,1325275663,7/17/2014 13:24:00,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169923,7/17/2014 13:34:11,,1325287107,7/17/2014 13:33:50,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,227,142,,234,167,causes,0.412081691846067,904552-FS1-4,"Mutations in the X linked cyclin dependent kinase like 5 (CDKL5) gene have been identified in patients with Rett syndrome, West syndrome, and X LINKED INFANTILE SPASMS sharing the common features of generally intractable early SEIZURES and mental retardation.",SEIZURES,X LINKED INFANTILE SPASMS,RO-has_definitional_manifestation
504169924,7/17/2014 10:30:37,,1325138417,7/17/2014 10:30:28,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY causes PRION PROTEIN,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169924,7/17/2014 10:32:04,,1325139742,7/17/2014 10:31:34,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169924,7/17/2014 10:41:44,,1325147414,7/17/2014 10:41:12,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169924,7/17/2014 11:05:10,,1325165106,7/17/2014 11:04:17,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169924,7/17/2014 12:11:09,,1325215225,7/17/2014 12:10:55,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169924,7/17/2014 12:12:28,,1325216239,7/17/2014 12:12:14,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169924,7/17/2014 13:56:01,,1325306741,7/17/2014 13:55:30,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,196,233,,208,272,causes,0.924500327042048,903808-FS1-4,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,RO-has_causative_agent
504169925,7/17/2014 10:32:29,,1325140024,7/17/2014 10:32:24,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169925,7/17/2014 10:38:56,,1325145138,7/17/2014 10:38:37,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,OSTEOGENESIS IMPERFECTA causes LOW BONE MASS,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169925,7/17/2014 11:30:18,,1325184521,7/17/2014 11:29:52,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,OSTEOGENESIS IMPERFECTA causes LOW BONE MASS,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169925,7/17/2014 11:34:35,,1325188701,7/17/2014 11:34:11,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169925,7/17/2014 12:07:08,,1325212056,7/17/2014 12:06:52,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,OSTEOGENESIS IMPERFECTA causes LOW BONE MASS,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169925,7/17/2014 13:02:24,,1325256951,7/17/2014 13:01:55,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169925,7/17/2014 13:06:03,,1325260254,7/17/2014 13:05:30,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,LOW BONE MASS causes OSTEOGENESIS IMPERFECTA,83,0,,95,23,causes,0.997054485501582,902453-FS1-4,"OSTEOGENESIS IMPERFECTA (OI) is a genetic disorder of increased bone fragility and LOW BONE MASS Severity varies widely, ranging from intrauterine fractures and perinatal lethality to very mild forms without fractures.",LOW BONE MASS,OSTEOGENESIS IMPERFECTA,RO-disease_has_primary_anatomic_site
504169926,7/17/2014 10:32:16,,1325139883,7/17/2014 10:32:11,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,BRONCHIECTASIS diagnosed by SEGMENTAL BRONCHI,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169926,7/17/2014 10:34:03,,1325141416,7/17/2014 10:33:57,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169926,7/17/2014 10:38:56,,1325145156,7/17/2014 10:38:37,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,BRONCHIECTASIS diagnosed by SEGMENTAL BRONCHI,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169926,7/17/2014 11:33:03,,1325187181,7/17/2014 11:32:18,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,no_relation,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169926,7/17/2014 11:35:48,,1325189824,7/17/2014 11:35:17,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,BRONCHIECTASIS diagnosed by SEGMENTAL BRONCHI,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169926,7/17/2014 11:51:29,,1325201136,7/17/2014 11:50:59,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169926,7/17/2014 13:06:32,,1325260674,7/17/2014 13:06:04,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,BRONCHIECTASIS diagnosed by SEGMENTAL BRONCHI,11,94,,27,108,diagnosed by,0.620173672946042,905364-FS1-13,"Of the 101 SEGMENTAL BRONCHI showing bronchiectasis on bronchography, CT correctly identified BRONCHIECTASIS in 98 segments (97%.",SEGMENTAL BRONCHI,BRONCHIECTASIS,RO-has_finding_site
504169927,7/17/2014 10:30:54,,1325138623,7/17/2014 10:30:45,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,PHEOCHROMOCYTOMA causes HYPERTENSION,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169927,7/17/2014 10:34:38,,1325141904,7/17/2014 10:34:26,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,PHEOCHROMOCYTOMA causes HYPERTENSION,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169927,7/17/2014 11:29:42,,1325183918,7/17/2014 11:28:58,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,PHEOCHROMOCYTOMA causes HYPERTENSION,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169927,7/17/2014 13:22:34,,1325274158,7/17/2014 13:21:51,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169927,7/17/2014 13:32:39,,1325285695,7/17/2014 13:32:18,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,PHEOCHROMOCYTOMA causes HYPERTENSION,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169927,7/17/2014 13:51:59,,1325302966,7/17/2014 13:51:39,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,PHEOCHROMOCYTOMA causes HYPERTENSION,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169927,7/17/2014 14:00:25,,1325311060,7/17/2014 14:00:03,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,PHEOCHROMOCYTOMA causes HYPERTENSION,72,0,,83,16,causes,1,902691-FS1-4,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA,RO-disease_may_have_finding
504169928,7/17/2014 10:32:35,,1325140109,7/17/2014 10:32:30,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,CHRONIC LYMPHOCYTIC LEUKAEMIA causes INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169928,7/17/2014 10:43:56,,1325149102,7/17/2014 10:43:41,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169928,7/17/2014 11:09:32,,1325168395,7/17/2014 11:09:25,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,CHRONIC LYMPHOCYTIC LEUKAEMIA causes INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169928,7/17/2014 11:28:11,,1325182691,7/17/2014 11:27:24,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS causes CHRONIC LYMPHOCYTIC LEUKAEMIA,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169928,7/17/2014 11:46:43,,1325197732,7/17/2014 11:46:11,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169928,7/17/2014 12:55:44,,1325251224,7/17/2014 12:55:17,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,CHRONIC LYMPHOCYTIC LEUKAEMIA causes INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169928,7/17/2014 13:21:26,,1325273163,7/17/2014 13:20:57,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,109,60,,163,89,causes,0.983078304622849,902791-FS1-4,We report a case of a 68 years old male patient treated for CHRONIC LYMPHOCYTIC LEUKAEMIA presenting a right INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS.,INGUINO CRURAL TENDER LYMPHADENOPATHY WITH PERIADENITIS,CHRONIC LYMPHOCYTIC LEUKAEMIA,RO-disease_may_have_finding
504169929,7/17/2014 10:21:44,,1325131519,7/17/2014 10:21:34,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,ELEVATED BP causes HYPERTENSION,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169929,7/17/2014 10:31:24,,1325139111,7/17/2014 10:31:17,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,ELEVATED BP causes HYPERTENSION,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169929,7/17/2014 10:41:38,,1325147309,7/17/2014 10:41:21,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,HYPERTENSION causes ELEVATED BP,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169929,7/17/2014 11:26:55,,1325181730,7/17/2014 11:25:48,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,ELEVATED BP causes HYPERTENSION,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169929,7/17/2014 12:56:49,,1325251975,7/17/2014 12:56:41,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,HYPERTENSION causes ELEVATED BP,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169929,7/17/2014 13:08:09,,1325261974,7/17/2014 13:07:47,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,ELEVATED BP causes HYPERTENSION,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169929,7/17/2014 13:37:53,,1325290051,7/17/2014 13:37:18,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,100,53,,110,65,causes,0.620173672946042,904506-FS1-4,We conclude that symptoms putatively associated with HYPERTENSION are common among ED patients with ELEVATED BP and their prevalence appears unrelated to BP value.,ELEVATED BP,HYPERTENSION,RO-has_definitional_manifestation
504169930,7/17/2014 11:35:16,,1325189294,7/17/2014 11:35:02,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,PLASMODIUM FALCIPARUM INFECTION causes MALARIA,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169930,7/17/2014 11:48:27,,1325198947,7/17/2014 11:48:03,instagc,0.6489,13763729,USA,"","",75.182.89.225,MALARIA causes PLASMODIUM FALCIPARUM INFECTION,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169930,7/17/2014 12:11:28,,1325215453,7/17/2014 12:11:08,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169930,7/17/2014 12:12:41,,1325216445,7/17/2014 12:11:48,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,MALARIA causes PLASMODIUM FALCIPARUM INFECTION,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169930,7/17/2014 12:28:24,,1325228629,7/17/2014 12:28:13,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,PLASMODIUM FALCIPARUM INFECTION causes MALARIA,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169930,7/17/2014 13:36:28,,1325288842,7/17/2014 13:35:56,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169930,7/17/2014 14:02:51,,1325313594,7/17/2014 14:02:35,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,246,398,,276,405,causes,0.324442842261525,903659-FS1-4,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169931,7/17/2014 10:33:40,,1325141081,7/17/2014 10:33:17,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169931,7/17/2014 10:46:07,,1325150836,7/17/2014 10:45:48,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,SPORADIC MENINGIOMA causes NEUROFIBROMATOSIS TYPE 2,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169931,7/17/2014 11:20:09,,1325176993,7/17/2014 11:19:46,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169931,7/17/2014 12:11:47,,1325215795,7/17/2014 12:11:28,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,NEUROFIBROMATOSIS TYPE 2 causes SPORADIC MENINGIOMA,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169931,7/17/2014 12:54:03,,1325249841,7/17/2014 12:53:53,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169931,7/17/2014 13:09:28,,1325262915,7/17/2014 13:08:56,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,NEUROFIBROMATOSIS TYPE 2 causes SPORADIC MENINGIOMA,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169931,7/17/2014 13:23:59,,1325275381,7/17/2014 13:23:09,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,101,62,,119,86,causes,0.905821627315676,906483-FS1-4,The authors investigated the role of somatic mutations of the NEUROFIBROMATOSIS TYPE 2 (NF2) gene in SPORADIC MENINGIOMA,SPORADIC MENINGIOMA,NEUROFIBROMATOSIS TYPE 2,RO-has_manifestation
504169932,7/17/2014 10:31:36,,1325139327,7/17/2014 10:31:32,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169932,7/17/2014 10:33:16,,1325140706,7/17/2014 10:32:34,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169932,7/17/2014 10:40:00,,1325146055,7/17/2014 10:39:44,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169932,7/17/2014 11:23:54,,1325179814,7/17/2014 11:23:23,prodege,0.5754,27934334,GBR,"","",86.130.153.15,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169932,7/17/2014 11:49:41,,1325199974,7/17/2014 11:49:15,instagc,0.6489,13763729,USA,"","",75.182.89.225,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169932,7/17/2014 11:55:51,,1325204084,7/17/2014 11:55:21,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169932,7/17/2014 12:24:36,,1325225468,7/17/2014 12:24:06,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,52,109,,91,118,treats,0.962250448649376,907719-FS1-2,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE,RO-may_treat
504169933,7/17/2014 10:42:54,,1325148283,7/17/2014 10:42:38,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169933,7/17/2014 11:06:06,,1325165674,7/17/2014 11:05:38,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169933,7/17/2014 11:19:45,,1325176695,7/17/2014 11:19:27,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169933,7/17/2014 11:25:53,,1325181104,7/17/2014 11:25:11,prodege,0.5754,27934334,GBR,"","",86.130.153.15,PANCREATIC ISLETS is location of INSULIN DEPENDENT DIABETES MELLITUS,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169933,7/17/2014 11:29:42,,1325183916,7/17/2014 11:28:58,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,PANCREATIC ISLETS is location of INSULIN DEPENDENT DIABETES MELLITUS,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169933,7/17/2014 11:36:14,,1325190311,7/17/2014 11:35:49,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169933,7/17/2014 11:45:47,,1325197080,7/17/2014 11:45:16,instagc,0.6489,13763729,USA,"","",75.182.89.225,PANCREATIC ISLETS is location of INSULIN DEPENDENT DIABETES MELLITUS,48,118,,64,153,is location of,0.549442255794756,902058-FS1-9,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS,RO-disease_has_primary_anatomic_site
504169934,7/17/2014 10:21:33,,1325131367,7/17/2014 10:21:26,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,LITHIUM treats BIPOLAR DISORDER,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169934,7/17/2014 10:30:17,,1325138159,7/17/2014 10:29:57,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,LITHIUM treats BIPOLAR DISORDER,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169934,7/17/2014 10:31:24,,1325139113,7/17/2014 10:31:17,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,LITHIUM treats BIPOLAR DISORDER,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169934,7/17/2014 10:41:57,,1325147540,7/17/2014 10:41:45,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,LITHIUM treats BIPOLAR DISORDER,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169934,7/17/2014 10:45:47,,1325150573,7/17/2014 10:45:22,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,LITHIUM treats BIPOLAR DISORDER,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169934,7/17/2014 11:03:07,,1325163657,7/17/2014 11:02:22,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,LITHIUM treats BIPOLAR DISORDER,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169934,7/17/2014 11:58:14,,1325205656,7/17/2014 11:57:40,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,53,0,,68,7,treats,1,908289-FS1-2,"LITHIUM treatment, initially considered specific for BIPOLAR DISORDER has since been shown to provide additional benefits in affective and other disorders.",BIPOLAR DISORDER,LITHIUM,RO-may_treat
504169935,7/17/2014 11:13:57,,1325172226,7/17/2014 11:13:40,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169935,7/17/2014 11:22:52,,1325179042,7/17/2014 11:22:29,prodege,0.5754,27934334,GBR,"","",86.130.153.15,POLIOVIRUS causes POLIOMYELITIS,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169935,7/17/2014 11:30:32,,1325184724,7/17/2014 11:30:19,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,POLIOVIRUS causes POLIOMYELITIS,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169935,7/17/2014 13:22:28,,1325274079,7/17/2014 13:22:03,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169935,7/17/2014 13:55:29,,1325306199,7/17/2014 13:54:55,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169935,7/17/2014 14:02:35,,1325313405,7/17/2014 14:02:17,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,POLIOVIRUS causes POLIOMYELITIS,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169935,7/17/2014 14:04:38,,1325315162,7/17/2014 14:04:19,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,POLIOVIRUS causes POLIOMYELITIS,39,111,,48,124,causes,0.488677777425221,903918-FS1-4,The proposed unifying model of natural POLIOVIRUS evolution has important implications for the epidemiology of POLIOMYELITIS,POLIOVIRUS,POLIOMYELITIS,RO-has_causative_agent
504169936,7/17/2014 11:07:31,,1325166750,7/17/2014 11:06:38,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169936,7/17/2014 11:09:12,,1325168072,7/17/2014 11:09:05,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,JAUNDICE causes HEPATIC CARCINOMA,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169936,7/17/2014 11:50:31,,1325200508,7/17/2014 11:50:07,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169936,7/17/2014 13:04:27,,1325258911,7/17/2014 13:03:55,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,JAUNDICE causes HEPATIC CARCINOMA,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169936,7/17/2014 13:23:59,,1325275420,7/17/2014 13:23:09,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169936,7/17/2014 13:33:06,,1325286185,7/17/2014 13:32:40,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169936,7/17/2014 13:52:38,,1325303614,7/17/2014 13:52:00,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,114,123,,121,140,causes,0.457495710997814,902602-FS1-4,"There are numerous side effects to anabolic steroids, including hypertension and atherosclerosis, blood clotting, JAUNDICE HEPATIC CARCINOMA tendon damage, psychiatric and behavioural effects and, in males, reduced fertility and gynaccomastia.",JAUNDICE,HEPATIC CARCINOMA,RO-disease_may_have_finding
504169937,7/17/2014 11:02:20,,1325163112,7/17/2014 11:01:54,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169937,7/17/2014 11:30:21,,1325184557,7/17/2014 11:29:49,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169937,7/17/2014 11:31:19,,1325185325,7/17/2014 11:31:02,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169937,7/17/2014 11:55:51,,1325204085,7/17/2014 11:55:21,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169937,7/17/2014 12:11:27,,1325215440,7/17/2014 12:11:10,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169937,7/17/2014 12:57:14,,1325252327,7/17/2014 12:57:07,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169937,7/17/2014 13:06:03,,1325260247,7/17/2014 13:05:30,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,170,141,,194,149,treats,0.997054485501582,908100-FS1-2,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN,RO-may_treat
504169938,7/17/2014 10:34:55,,1325142126,7/17/2014 10:34:47,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169938,7/17/2014 10:43:17,,1325148609,7/17/2014 10:42:53,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,SALMONELLA ISOLATES causes AMPICILLIN,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169938,7/17/2014 11:15:07,,1325173120,7/17/2014 11:14:52,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169938,7/17/2014 11:22:28,,1325178760,7/17/2014 11:22:05,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169938,7/17/2014 11:51:29,,1325201137,7/17/2014 11:50:59,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169938,7/17/2014 11:59:05,,1325206377,7/17/2014 11:58:53,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,AMPICILLIN causes SALMONELLA ISOLATES,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169938,7/17/2014 12:56:40,,1325251893,7/17/2014 12:56:11,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,0,80,,18,90,causes,0.316227766016838,908309-FS1-4,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169939,7/17/2014 10:26:11,,1325134774,7/17/2014 10:25:52,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,MALIGNANT HYPERTHERMIA SYNDROME diagnosed by HALOTHANE,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169939,7/17/2014 10:34:13,,1325141539,7/17/2014 10:34:05,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,HALOTHANE diagnosed by MALIGNANT HYPERTHERMIA SYNDROME,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169939,7/17/2014 11:08:44,,1325167806,7/17/2014 11:08:28,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,MALIGNANT HYPERTHERMIA SYNDROME diagnosed by HALOTHANE,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169939,7/17/2014 11:15:45,,1325173683,7/17/2014 11:15:29,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,MALIGNANT HYPERTHERMIA SYNDROME diagnosed by HALOTHANE,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169939,7/17/2014 11:25:10,,1325180621,7/17/2014 11:24:43,prodege,0.5754,27934334,GBR,"","",86.130.153.15,MALIGNANT HYPERTHERMIA SYNDROME diagnosed by HALOTHANE,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169939,7/17/2014 11:31:01,,1325185095,7/17/2014 11:30:49,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,MALIGNANT HYPERTHERMIA SYNDROME diagnosed by HALOTHANE,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169939,7/17/2014 11:34:10,,1325188221,7/17/2014 11:33:43,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,MALIGNANT HYPERTHERMIA SYNDROME diagnosed by HALOTHANE,92,68,,122,77,diagnosed by,0.997054485501582,906757-FS1-13,"At the end of the growth period, when the pigs were challenged with HALOTHANE to detect the MALIGNANT HYPERTHERMIA SYNDROME 3 pigs were found to be susceptible.",MALIGNANT HYPERTHERMIA SYNDROME,HALOTHANE,RO-may_diagnose
504169940,7/17/2014 10:21:53,,1325131601,7/17/2014 10:21:45,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,PLATELET SEQUESTRATION causes THROMBOCYTOPENIA,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169940,7/17/2014 10:32:35,,1325140113,7/17/2014 10:32:30,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,THROMBOCYTOPENIA causes PLATELET SEQUESTRATION,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169940,7/17/2014 11:05:37,,1325165352,7/17/2014 11:05:11,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,PLATELET SEQUESTRATION causes THROMBOCYTOPENIA,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169940,7/17/2014 11:08:27,,1325167593,7/17/2014 11:08:16,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,THROMBOCYTOPENIA causes PLATELET SEQUESTRATION,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169940,7/17/2014 11:20:09,,1325176989,7/17/2014 11:19:46,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169940,7/17/2014 11:23:22,,1325179398,7/17/2014 11:22:53,prodege,0.5754,27934334,GBR,"","",86.130.153.15,THROMBOCYTOPENIA causes PLATELET SEQUESTRATION,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169940,7/17/2014 12:08:11,,1325212780,7/17/2014 12:07:35,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,35,118,,50,140,causes,0.857492925712544,904751-FS1-4,"In most recently infected patients THROMBOCYTOPENIA is due to accelerated platelet destruction; in these patients the PLATELET SEQUESTRATION is predominantly splenic, and splenectomy is usually effective.",THROMBOCYTOPENIA,PLATELET SEQUESTRATION,RO-has_definitional_manifestation
504169941,7/17/2014 10:44:26,,1325149474,7/17/2014 10:44:10,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,JOINTS is location of ARTHRITIS,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169941,7/17/2014 11:06:29,,1325165959,7/17/2014 11:06:07,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,JOINTS is location of ARTHRITIS,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169941,7/17/2014 11:13:11,,1325171594,7/17/2014 11:12:34,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,JOINTS is location of ARTHRITIS,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169941,7/17/2014 11:35:01,,1325189007,7/17/2014 11:34:35,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169941,7/17/2014 12:10:19,,1325214485,7/17/2014 12:10:08,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,JOINTS is location of ARTHRITIS,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169941,7/17/2014 12:54:42,,1325250381,7/17/2014 12:54:32,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,JOINTS is location of ARTHRITIS,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169941,7/17/2014 13:01:53,,1325256489,7/17/2014 13:01:37,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,JOINTS is location of ARTHRITIS,76,36,,81,45,is location of,0.940720868383597,905445-FS1-9,"Among them, the most common include ARTHRITIS of the large and medium sized JOINTS in FMF and CINCA, arthralgia in HIDS, and myalgia or pseudo fasciitis in TRAPS.",JOINTS,ARTHRITIS,RO-has_finding_site
504169942,7/17/2014 10:42:54,,1325148277,7/17/2014 10:42:38,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,CANCER OF THE CERVIX is location of UTERINE CERVIX,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169942,7/17/2014 11:09:33,,1325168424,7/17/2014 11:08:58,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,UTERINE CERVIX is location of CANCER OF THE CERVIX,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169942,7/17/2014 11:27:47,,1325182455,7/17/2014 11:27:29,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,UTERINE CERVIX is location of CANCER OF THE CERVIX,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169942,7/17/2014 11:28:11,,1325182682,7/17/2014 11:27:24,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,UTERINE CERVIX is location of CANCER OF THE CERVIX,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169942,7/17/2014 11:36:14,,1325190305,7/17/2014 11:35:49,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169942,7/17/2014 12:13:34,,1325216987,7/17/2014 12:12:43,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,UTERINE CERVIX is location of CANCER OF THE CERVIX,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169942,7/17/2014 12:25:29,,1325226298,7/17/2014 12:25:06,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,UTERINE CERVIX is location of CANCER OF THE CERVIX,28,115,,41,135,is location of,0.505076272276105,902354-FS1-9,Persistent infection of the UTERINE CERVIX with high risk human papillomaviruses (HPV) is causally associated with CANCER OF THE CERVIX,UTERINE CERVIX,CANCER OF THE CERVIX,RO-disease_has_primary_anatomic_site
504169943,7/17/2014 10:44:09,,1325149266,7/17/2014 10:43:38,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,ANGINA causes BEPRIDIL,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169943,7/17/2014 10:44:12,,1325149304,7/17/2014 10:43:57,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169943,7/17/2014 11:07:07,,1325166431,7/17/2014 11:06:45,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,ANGINA causes BEPRIDIL,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169943,7/17/2014 11:08:33,,1325167658,7/17/2014 11:07:31,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,BEPRIDIL causes ANGINA,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169943,7/17/2014 11:29:50,,1325184072,7/17/2014 11:29:32,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169943,7/17/2014 11:51:59,,1325201443,7/17/2014 11:51:30,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169943,7/17/2014 12:01:08,,1325207658,7/17/2014 12:00:48,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,139,191,,144,199,causes,0.441726104299386,908351-FS1-4,"Five of 15 patients receiving bepridil did not experience angina during treadmill exercise; in the remaining 10 patients, time to onset of ANGINA during exercise was 5.7 +/  0.9 minutes with BEPRIDIL as opposed to 4.5 +/  0.8 minutes with placebo (p less than 0.05.",ANGINA,BEPRIDIL,RO-may_treat
504169944,7/17/2014 10:43:56,,1325149096,7/17/2014 10:43:41,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169944,7/17/2014 11:32:31,,1325186622,7/17/2014 11:31:56,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169944,7/17/2014 12:00:15,,1325207006,7/17/2014 11:59:45,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169944,7/17/2014 12:24:06,,1325225100,7/17/2014 12:23:17,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169944,7/17/2014 13:37:16,,1325289541,7/17/2014 13:36:52,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169944,7/17/2014 13:53:08,,1325304174,7/17/2014 13:52:39,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169944,7/17/2014 14:02:51,,1325313592,7/17/2014 14:02:35,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,PLASMODIUM FALCIPARUM INFECTION treats MALARIA,246,398,,276,405,treats,0.324442842261525,903659-FS1-2,"malaria  Dihydroartemisinin piperaquine against multidrug resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial  Artesunate combinations for treatment of malaria: meta analysis  Efficacy of the RTS,S/AS02A vaccine against PLASMODIUM FALCIPARUM INFECTION and disease in young African children: randomised controlled trial  Combination treatments for uncomplicated falciparum MALARIA in Kampala, Uganda: randomised clinical trial  Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number  Supervised versus unsupervised intake of six dose artemether lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial  Amodiaquine alone.",PLASMODIUM FALCIPARUM INFECTION,MALARIA,RO-has_causative_agent
504169945,7/17/2014 11:15:45,,1325173680,7/17/2014 11:15:29,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169945,7/17/2014 11:29:48,,1325184040,7/17/2014 11:29:17,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169945,7/17/2014 11:50:06,,1325200224,7/17/2014 11:49:42,instagc,0.6489,13763729,USA,"","",75.182.89.225,CLL treats LYMPHADENOPATHY,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169945,7/17/2014 12:11:28,,1325215469,7/17/2014 12:11:08,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,CLL treats LYMPHADENOPATHY,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169945,7/17/2014 12:24:06,,1325225099,7/17/2014 12:23:17,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169945,7/17/2014 12:56:10,,1325251547,7/17/2014 12:55:46,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,CLL treats LYMPHADENOPATHY,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169945,7/17/2014 13:22:02,,1325273724,7/17/2014 13:21:27,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,82,131,,96,134,treats,0.905821627315676,902686-FS1-2,"? In patients with rapidly advancing disease characterized by B symptoms, massive LYMPHADENOPATHY and hepatosplenomegaly, consider CLL transformation (see  disease specific drug treatment in patients with transformed CLL.",LYMPHADENOPATHY,CLL,RO-disease_may_have_finding
504169946,7/17/2014 10:34:26,,1325141713,7/17/2014 10:34:15,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,no_relation,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169946,7/17/2014 11:03:07,,1325163648,7/17/2014 11:02:22,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,OBSESSIVE COMPULSIVE NEUROSIS diagnosed by ANXIETY,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169946,7/17/2014 11:19:25,,1325176476,7/17/2014 11:19:14,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169946,7/17/2014 11:55:20,,1325203699,7/17/2014 11:55:04,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169946,7/17/2014 12:11:48,,1325215798,7/17/2014 12:11:30,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,ANXIETY diagnosed by OBSESSIVE COMPULSIVE NEUROSIS,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169946,7/17/2014 12:55:16,,1325250853,7/17/2014 12:54:58,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169946,7/17/2014 13:05:29,,1325259812,7/17/2014 13:04:56,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,OBSESSIVE COMPULSIVE NEUROSIS diagnosed by ANXIETY,79,106,,85,135,diagnosed by,0.312347523777212,904918-FS1-13,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169947,7/17/2014 10:44:26,,1325149489,7/17/2014 10:44:10,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,GRANISETRON treats EMESIS,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169947,7/17/2014 11:09:42,,1325168568,7/17/2014 11:09:33,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,EMESIS treats GRANISETRON,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169947,7/17/2014 12:00:48,,1325207400,7/17/2014 12:00:16,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,EMESIS treats GRANISETRON,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169947,7/17/2014 13:09:28,,1325262918,7/17/2014 13:08:56,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,GRANISETRON treats EMESIS,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169947,7/17/2014 13:22:34,,1325274156,7/17/2014 13:21:51,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169947,7/17/2014 13:33:06,,1325286183,7/17/2014 13:32:40,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,GRANISETRON treats EMESIS,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169947,7/17/2014 13:53:08,,1325304202,7/17/2014 13:52:39,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,344,287,,349,298,treats,0.993127066322841,907359-FS1-2,The object of the study was to determine whether dexamethasone improved the efficacy of the serotonin receptor (5 HT3) antagonist granisetron in controlling acute (within 24 h) emesis in cancer patients receiving high dose cisplatin chemotherapy and to ascertain whether continuation of GRANISETRON after 24 h reduces the occurrence of delayed EMESIS,EMESIS,GRANISETRON,RO-may_prevent
504169948,7/17/2014 10:44:12,,1325149305,7/17/2014 10:43:57,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,EPILEPSY causes EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169948,7/17/2014 11:27:39,,1325182289,7/17/2014 11:26:28,prodege,0.5754,27934334,GBR,"","",86.130.153.15,EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES causes EPILEPSY,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169948,7/17/2014 11:32:31,,1325186626,7/17/2014 11:31:56,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,EPILEPSY causes EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169948,7/17/2014 13:03:54,,1325258328,7/17/2014 13:03:31,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES causes EPILEPSY,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169948,7/17/2014 13:25:25,,1325276753,7/17/2014 13:24:53,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES causes EPILEPSY,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169948,7/17/2014 13:35:14,,1325287950,7/17/2014 13:34:53,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169948,7/17/2014 14:03:05,,1325313807,7/17/2014 14:02:52,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,EPILEPSY causes EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,116,201,,162,209,causes,0.481543412343077,904940-FS1-4,"Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES under conditions of animal models of EPILEPSY; pharmacological blocking of galanin receptors exerted proconvulsant effects.",EPILEPTIC ACTIVITY ATTENUATED SEIZURE RESPONSES,EPILEPSY,RO-has_definitional_manifestation
504169949,7/17/2014 10:29:55,,1325137858,7/17/2014 10:29:38,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169949,7/17/2014 11:07:42,,1325166929,7/17/2014 11:07:28,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,TUBEROUS SCLEROSIS causes TONGUE BASE HAMARTOMA,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169949,7/17/2014 11:14:51,,1325172934,7/17/2014 11:14:34,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169949,7/17/2014 11:27:28,,1325182140,7/17/2014 11:26:56,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169949,7/17/2014 11:29:13,,1325183397,7/17/2014 11:28:33,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169949,7/17/2014 11:31:55,,1325185971,7/17/2014 11:31:29,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,no_relation,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169949,7/17/2014 12:28:51,,1325229041,7/17/2014 12:28:25,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,107,67,,124,88,causes,0.674199862463242,900150-FS1-4,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA,RO-cause_of
504169950,7/17/2014 10:42:05,,1325147636,7/17/2014 10:41:39,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,LYMPH NODE METASTASIS causes METASTATIC LESIONS,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169950,7/17/2014 11:06:36,,1325166034,7/17/2014 11:06:07,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,LYMPH NODE METASTASIS causes METASTATIC LESIONS,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169950,7/17/2014 11:30:54,,1325184993,7/17/2014 11:30:22,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,LYMPH NODE METASTASIS causes METASTATIC LESIONS,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169950,7/17/2014 12:10:07,,1325214344,7/17/2014 12:09:27,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169950,7/17/2014 12:28:13,,1325228481,7/17/2014 12:27:30,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,METASTATIC LESIONS causes LYMPH NODE METASTASIS,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169950,7/17/2014 13:07:46,,1325261599,7/17/2014 13:07:08,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,METASTATIC LESIONS causes LYMPH NODE METASTASIS,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169950,7/17/2014 13:17:10,,1325269430,7/17/2014 13:16:27,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,232,102,,249,123,causes,0.645497224367903,901642-FS1-4,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS,RO-disease_has_finding
504169951,7/17/2014 10:29:37,,1325137558,7/17/2014 10:29:06,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169951,7/17/2014 10:31:59,,1325139682,7/17/2014 10:31:37,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,HIV INFECTION causes HUMAN IMMUNODEFICIENCY VIRUS (HIV),23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169951,7/17/2014 11:16:14,,1325173974,7/17/2014 11:15:47,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169951,7/17/2014 11:57:11,,1325204859,7/17/2014 11:56:38,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169951,7/17/2014 13:51:37,,1325302529,7/17/2014 13:51:10,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169951,7/17/2014 14:03:20,,1325314073,7/17/2014 14:03:07,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169951,7/17/2014 14:04:18,,1325314875,7/17/2014 14:03:56,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,HUMAN IMMUNODEFICIENCY VIRUS (HIV) causes HIV INFECTION,23,148,,56,161,causes,0.312771621085612,903769-FS1-4,The Tat protein of the HUMAN IMMUNODEFICIENCY VIRUS (HIV) has been implicated in the pathophysiology of the neurocognitive deficits associated with HIV INFECTION,HUMAN IMMUNODEFICIENCY VIRUS (HIV),HIV INFECTION,RO-has_causative_agent
504169952,7/17/2014 11:10:42,,1325169382,7/17/2014 11:09:59,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169952,7/17/2014 12:09:25,,1325213680,7/17/2014 12:08:53,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169952,7/17/2014 12:26:57,,1325227319,7/17/2014 12:26:42,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169952,7/17/2014 13:16:26,,1325268740,7/17/2014 13:15:35,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169952,7/17/2014 13:33:49,,1325286704,7/17/2014 13:33:31,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169952,7/17/2014 13:56:29,,1325307188,7/17/2014 13:56:03,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169952,7/17/2014 14:03:05,,1325313806,7/17/2014 14:02:52,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,SULBACTAM AND AMPICILLIN COMBINATION treats SOFT TISSUE INFECTIONS,90,4,,111,40,treats,0.997054485501582,908272-FS1-2,The SULBACTAM AND AMPICILLIN COMBINATION is an effective combination for the treatment of SOFT TISSUE INFECTIONS,SOFT TISSUE INFECTIONS,SULBACTAM AND AMPICILLIN COMBINATION,RO-may_treat
504169953,7/17/2014 10:31:01,,1325138758,7/17/2014 10:30:54,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,CIRRHOSIS treats MILK THISTLE,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169953,7/17/2014 10:35:04,,1325142275,7/17/2014 10:34:57,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,MILK THISTLE treats CIRRHOSIS,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169953,7/17/2014 11:07:31,,1325166767,7/17/2014 11:06:38,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169953,7/17/2014 11:14:51,,1325172935,7/17/2014 11:14:34,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169953,7/17/2014 11:28:32,,1325182934,7/17/2014 11:27:40,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169953,7/17/2014 11:29:31,,1325183751,7/17/2014 11:29:16,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,MILK THISTLE treats CIRRHOSIS,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169953,7/17/2014 13:36:51,,1325289201,7/17/2014 13:36:29,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,182,157,,190,169,treats,0.790569415042095,907669-FS1-2,"Alternative Therapies for Hepatitis     Normal; Alternative Therapies for Hepatitis  Therapy Best Evidencea Probably Usefulb Least Evidencec         Herbals MILK THISTLE (hepatitis, CIRRHOSIS 70 140 mg t.i.d.",CIRRHOSIS,MILK THISTLE,RO-may_treat
504169954,7/17/2014 10:42:52,,1325148256,7/17/2014 10:42:19,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,HAEMOPHILIA A causes VIII (FVIII) INHIBITORS,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169954,7/17/2014 11:03:42,,1325164028,7/17/2014 11:03:09,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,HAEMOPHILIA A causes VIII (FVIII) INHIBITORS,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169954,7/17/2014 11:51:59,,1325201446,7/17/2014 11:51:30,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169954,7/17/2014 13:17:50,,1325269930,7/17/2014 13:17:11,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,VIII (FVIII) INHIBITORS causes HAEMOPHILIA A,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169954,7/17/2014 13:34:35,,1325287385,7/17/2014 13:34:12,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169954,7/17/2014 13:57:18,,1325307973,7/17/2014 13:56:59,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169954,7/17/2014 14:00:25,,1325311061,7/17/2014 14:00:03,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,HAEMOPHILIA A causes VIII (FVIII) INHIBITORS,103,25,,115,48,causes,0.957826285221151,906352-FS1-4,"The occurrence of factor VIII (FVIII) INHIBITORS is one of the major complications of the treatment of HAEMOPHILIA A We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors.",HAEMOPHILIA A,VIII (FVIII) INHIBITORS,RO-has_manifestation
504169955,7/17/2014 10:41:11,,1325146970,7/17/2014 10:40:47,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169955,7/17/2014 11:08:54,,1325167905,7/17/2014 11:08:45,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169955,7/17/2014 12:07:34,,1325212411,7/17/2014 12:07:09,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169955,7/17/2014 13:06:32,,1325260673,7/17/2014 13:06:04,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169955,7/17/2014 13:21:50,,1325273539,7/17/2014 13:21:00,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,WOLFRAM SYNDROME causes UNEXPLAINED OPTIC ATROPHY,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169955,7/17/2014 13:36:28,,1325288844,7/17/2014 13:35:56,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169955,7/17/2014 13:54:54,,1325305725,7/17/2014 13:54:32,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,UNEXPLAINED OPTIC ATROPHY causes WOLFRAM SYNDROME,89,13,,113,29,causes,0.824163383692134,906228-FS1-4,"Although the WOLFRAM SYNDROME is rare, it should be considered in diabetic patients with UNEXPLAINED OPTIC ATROPHY and hearing loss or with polyuria and polydipsia in the presence of adequate blood sugar control.",UNEXPLAINED OPTIC ATROPHY,WOLFRAM SYNDROME,RO-has_manifestation
504169956,7/17/2014 10:43:13,,1325148554,7/17/2014 10:42:56,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169956,7/17/2014 11:05:10,,1325165116,7/17/2014 11:04:17,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,AMPICILLIN treats SALMONELLA ISOLATES,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169956,7/17/2014 11:07:52,,1325167076,7/17/2014 11:07:42,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,SALMONELLA ISOLATES treats AMPICILLIN,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169956,7/17/2014 12:12:44,,1325216448,7/17/2014 12:12:30,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,AMPICILLIN treats SALMONELLA ISOLATES,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169956,7/17/2014 13:24:21,,1325275701,7/17/2014 13:24:00,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169956,7/17/2014 13:33:49,,1325286705,7/17/2014 13:33:31,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169956,7/17/2014 14:02:16,,1325313062,7/17/2014 14:02:04,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,AMPICILLIN treats SALMONELLA ISOLATES,0,80,,18,90,treats,0.843274042711568,908309-FS1-2,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN,RO-may_treat
504169957,7/17/2014 10:31:16,,1325138935,7/17/2014 10:31:10,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169957,7/17/2014 10:31:17,,1325138942,7/17/2014 10:30:48,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169957,7/17/2014 10:34:55,,1325142116,7/17/2014 10:34:47,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169957,7/17/2014 10:43:38,,1325148917,7/17/2014 10:43:17,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169957,7/17/2014 11:09:05,,1325168025,7/17/2014 11:08:54,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169957,7/17/2014 11:29:50,,1325184074,7/17/2014 11:29:32,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169957,7/17/2014 11:57:11,,1325204855,7/17/2014 11:56:38,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,CERVIX is location of CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),57,75,,62,117,is location of,0.884651736929383,902157-FS1-9,"Altogether, 1924 women were studied: 42.8% with a normal CERVIX 16.2% with CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I), 12.7% with CIN II, 20.8% with CIN III, and 7.6% with invasive cervical cancer (ICC.",CERVIX,CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN I),RO-disease_has_primary_anatomic_site
504169958,7/17/2014 10:42:05,,1325147635,7/17/2014 10:41:39,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,TESTICULAR GERM CELL CANCER causes CONTRALATERAL TESTIS,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169958,7/17/2014 11:11:04,,1325169645,7/17/2014 11:10:44,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169958,7/17/2014 11:16:36,,1325174348,7/17/2014 11:16:15,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169958,7/17/2014 11:33:36,,1325187689,7/17/2014 11:33:04,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,no_relation,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169958,7/17/2014 11:59:25,,1325206572,7/17/2014 11:59:06,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,no_relation,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169958,7/17/2014 12:08:34,,1325213090,7/17/2014 12:08:12,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,no_relation,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169958,7/17/2014 12:27:29,,1325227797,7/17/2014 12:26:59,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,no_relation,20,68,,39,95,causes,0.333333333333333,902445-FS1-4,CIS is found in the CONTRALATERAL TESTIS in 5% of the patients with TESTICULAR GERM CELL CANCER,CONTRALATERAL TESTIS,TESTICULAR GERM CELL CANCER,RO-disease_has_primary_anatomic_site
504169959,7/17/2014 10:21:17,,1325131141,7/17/2014 10:21:01,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169959,7/17/2014 11:06:06,,1325165685,7/17/2014 11:05:38,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169959,7/17/2014 11:57:39,,1325205224,7/17/2014 11:57:12,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169959,7/17/2014 12:08:52,,1325213332,7/17/2014 12:08:35,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169959,7/17/2014 12:54:30,,1325250148,7/17/2014 12:54:18,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169959,7/17/2014 13:04:54,,1325259288,7/17/2014 13:04:29,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169959,7/17/2014 13:24:52,,1325276276,7/17/2014 13:24:22,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,INSULIN THERAPY treats TYPE 2 DIABETES,49,84,,63,99,treats,0.986393923832143,907826-FS1-2,"Unfortunately, the majority of CKD patients with TYPE 2 DIABETES eventually require INSULIN THERAPY.",TYPE 2 DIABETES,INSULIN THERAPY,RO-may_treat
504169960,7/17/2014 11:04:16,,1325164410,7/17/2014 11:03:43,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,TB diagnosed by PPD,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169960,7/17/2014 11:19:25,,1325176477,7/17/2014 11:19:14,prodege,0.6456,15439740,AUS,02,Jannali,27.96.208.89,no_relation,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169960,7/17/2014 13:17:10,,1325269445,7/17/2014 13:16:27,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,TB diagnosed by PPD,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169960,7/17/2014 13:33:29,,1325286404,7/17/2014 13:33:08,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,TB diagnosed by PPD,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169960,7/17/2014 13:53:27,,1325304539,7/17/2014 13:53:09,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,TB diagnosed by PPD,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169960,7/17/2014 14:01:40,,1325312424,7/17/2014 14:01:19,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169960,7/17/2014 14:04:18,,1325314874,7/17/2014 14:03:56,neodev,0.4184,18339121,USA,SC,Sumter,173.93.188.194,TB diagnosed by PPD,3,22,,4,25,diagnosed by,0.842700971600384,906829-FS1-13,"If TB is a concern, a PPD is performed.",TB,PPD,RO-may_diagnose
504169961,7/17/2014 10:30:37,,1325138413,7/17/2014 10:30:28,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169961,7/17/2014 10:31:33,,1325139278,7/17/2014 10:31:19,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169961,7/17/2014 10:34:46,,1325141997,7/17/2014 10:34:39,clixsense,0.8111,27793793,GBR,C5,Chester,151.230.27.155,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169961,7/17/2014 10:42:37,,1325148054,7/17/2014 10:42:22,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169961,7/17/2014 11:45:15,,1325196662,7/17/2014 11:44:53,instagc,0.6489,13763729,USA,"","",75.182.89.225,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169961,7/17/2014 11:59:45,,1325206734,7/17/2014 11:59:27,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169961,7/17/2014 14:01:18,,1325312041,7/17/2014 14:01:10,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,LEVODOPA treats PARKINSON'S DISEASE,27,65,,45,73,treats,0.997054485501582,908327-FS1-2,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA,RO-may_treat
504169962,7/17/2014 10:42:21,,1325147819,7/17/2014 10:42:07,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,IBUPROFEN treats INFLAMMATION,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169962,7/17/2014 11:22:03,,1325178483,7/17/2014 11:21:22,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169962,7/17/2014 11:26:55,,1325181729,7/17/2014 11:25:48,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,IBUPROFEN treats INFLAMMATION,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169962,7/17/2014 11:33:42,,1325187785,7/17/2014 11:33:26,fusioncash,0.6519,7012325,USA,CT,Stamford,24.185.182.15,IBUPROFEN treats INFLAMMATION,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169962,7/17/2014 12:12:28,,1325216229,7/17/2014 12:12:14,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,IBUPROFEN treats INFLAMMATION,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169962,7/17/2014 13:02:41,,1325257255,7/17/2014 13:02:25,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,IBUPROFEN treats INFLAMMATION,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169962,7/17/2014 13:35:14,,1325287947,7/17/2014 13:34:53,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,no_relation,89,52,,100,61,treats,0.911322376865767,908045-FS1-2,In contrast to previous studies with its metabolite IBUPROFEN reparixin does not enhance INFLAMMATION in this model.,INFLAMMATION,IBUPROFEN,RO-may_treat
504169963,7/17/2014 11:25:17,,1325180692,7/17/2014 11:24:52,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169963,7/17/2014 11:47:37,,1325198352,7/17/2014 11:47:07,instagc,0.6489,13763729,USA,"","",75.182.89.225,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169963,7/17/2014 12:57:06,,1325252206,7/17/2014 12:56:58,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169963,7/17/2014 13:20:15,,1325272115,7/17/2014 13:19:35,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169963,7/17/2014 13:22:02,,1325273725,7/17/2014 13:21:27,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169963,7/17/2014 13:58:03,,1325308760,7/17/2014 13:57:19,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169963,7/17/2014 14:01:18,,1325312036,7/17/2014 14:01:10,clixsense,0.6306,15189335,GBR,T5,Aberdeen,90.218.222.164,no_relation,79,106,,85,135,treats,0.312347523777212,904918-FS1-2,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS,RO-has_definitional_manifestation
504169964,7/17/2014 10:30:54,,1325138636,7/17/2014 10:30:45,clixsense,0.8667,19162475,GBR,M3,Frome,82.33.126.30,HEART is location of MYOCARDIAL ISCHAEMIA,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169964,7/17/2014 10:41:38,,1325147308,7/17/2014 10:41:21,clixsense,0.8083,19803139,NLD,06,Veldhoven,212.61.84.196,HEART is location of MYOCARDIAL ISCHAEMIA,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169964,7/17/2014 12:08:34,,1325213079,7/17/2014 12:08:12,elite,0.6437,28503042,USA,NJ,Woodbridge,54.191.150.115,HEART is location of MYOCARDIAL ISCHAEMIA,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169964,7/17/2014 12:25:47,,1325226424,7/17/2014 12:25:30,prodege,0.7034,7664351,USA,NY,Cicero,74.111.0.21,HEART is location of MYOCARDIAL ISCHAEMIA,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169964,7/17/2014 12:56:57,,1325252090,7/17/2014 12:56:50,clixsense,0.7115,16827630,GBR,A7,Birmingham,86.146.169.103,HEART is location of MYOCARDIAL ISCHAEMIA,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169964,7/17/2014 13:15:34,,1325268052,7/17/2014 13:14:39,clixsense,0.5029,6334612,USA,OH,Cleveland,108.225.254.58,no_relation,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169964,7/17/2014 13:35:53,,1325288382,7/17/2014 13:35:34,prodege,0.5459,28039757,GBR,L8,Southport,109.155.158.54,HEART is location of MYOCARDIAL ISCHAEMIA,143,108,,147,128,is location of,0.983078304622849,905220-FS1-9,"Functional and structural alterations of myocardial mitochondria were investigated after four conditions of MYOCARDIAL ISCHAEMIA in guinea pig HEART: (1) 45 min complete ischaemia, (2) 60 min low flow anoxic perfusion (0.3 ml/g wet weight per minute) with a modified Tyrode solution, (3) as (2) with 0.4 mM palmitic acid added to the perfusate, and (4) as (2) with 0.4 mM oleic acid added.",HEART,MYOCARDIAL ISCHAEMIA,RO-has_finding_site
504169965,7/17/2014 11:03:42,,1325164026,7/17/2014 11:03:09,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,HASHIMOTO'S THYROIDITIS is location of THYROID,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169965,7/17/2014 11:25:10,,1325180626,7/17/2014 11:24:43,prodege,0.5754,27934334,GBR,"","",86.130.153.15,THYROID is location of HASHIMOTO'S THYROIDITIS,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169965,7/17/2014 11:30:48,,1325184868,7/17/2014 11:30:33,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,THYROID is location of HASHIMOTO'S THYROIDITIS,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169965,7/17/2014 11:56:37,,1325204543,7/17/2014 11:56:17,tremorgames,0.5999,24449707,CAN,QC,Laval,96.21.249.72,THYROID is location of HASHIMOTO'S THYROIDITIS,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169965,7/17/2014 13:03:54,,1325258327,7/17/2014 13:03:31,neodev,0.6065,21515166,NLD,11,Nootdorp,83.86.58.179,THYROID is location of HASHIMOTO'S THYROIDITIS,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169965,7/17/2014 13:22:28,,1325274080,7/17/2014 13:22:03,prodege,0.6851,24945126,GBR,F6,Romford,82.12.220.44,THYROID is location of HASHIMOTO'S THYROIDITIS,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169965,7/17/2014 13:54:54,,1325305731,7/17/2014 13:54:32,clixsense,0.619,6579377,CAN,BC,Richmond,174.6.142.227,no_relation,28,16,,34,39,is location of,0.939793423488437,902140-FS1-9,Pathogenesis of HASHIMOTO'S THYROIDITIS is largely cell mediated immune destruction of the THYROID,THYROID,HASHIMOTO'S THYROIDITIS,RO-disease_has_primary_anatomic_site
504169966,7/17/2014 10:34:54,,1325142089,7/17/2014 10:34:23,instagc,0.8444,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169966,7/17/2014 10:40:46,,1325146689,7/17/2014 10:40:20,prodege,0.7444,9525153,CAN,ON,Toronto,65.95.92.180,INSULIN INDUCED HYPOGLYCEMIA causes GLUCAGON,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169966,7/17/2014 11:09:32,,1325168403,7/17/2014 11:09:25,instagc,0.6656,23149109,USA,NC,Durham,75.189.206.205,GLUCAGON causes INSULIN INDUCED HYPOGLYCEMIA,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169966,7/17/2014 11:10:42,,1325169386,7/17/2014 11:09:59,clixsense,0.6811,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169966,7/17/2014 11:22:03,,1325178482,7/17/2014 11:21:22,prodege,0.5754,27934334,GBR,"","",86.130.153.15,no_relation,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169966,7/17/2014 11:25:47,,1325180991,7/17/2014 11:25:19,gifthulk,0.71,21916793,GBR,"","",87.115.178.12,no_relation,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
504169966,7/17/2014 11:32:17,,1325186315,7/17/2014 11:31:16,vivatic,0.5949,25451531,GBR,"","",83.67.28.193,INSULIN INDUCED HYPOGLYCEMIA causes GLUCAGON,45,4,,72,12,causes,0.377964473009227,908243-FS1-4,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON,RO-may_treat
